**Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine for Schistosomiasis**

Rashika El Ridi and Hatem Tallima

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/52922

## **1. Introduction**

The field of schistosomiasis vaccine has suffered from several entrenched dogmas, which have delayed progress.

The first dogma states that the main mechanism of innate and acquired immunity-related parasite attrition is antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC has been shown to effectively mediate killing of 3-, 18- or 24 hr-old schistosomula in human, mouse, and rat models. However, this phenomenon is of no in vivo relevance as larvae of this age are still in the epidermis, impervious to host immune attacks. Intact, healthy older larvae, pre-adults and adult schistosomes are entirely invisible to the immune system, and thus, are never threatened by ADCC in vitro or in vivo. Concurrently, the immune effectors "hunt" for larvae in the pulmonary capillaries, proposed by von Lichtenberg et al. in 1977 [1] as a plausible mechanism for resistance to infection, was entirely neglected, and never men‐ tioned or referred to.

Second dogma is to consider parasite surface membrane antigens of great importance as vaccine antigens, because they reside at the host-parasite interface, and were shown to in‐ duce robust immune responses. However, schistosome surface membrane molecules are hidden, inaccessible to host antibodies, and accordingly, induced immune effectors are un‐ able to interact with the parasite.

Third, stressing that Th1 immune responses are the pillars for acquired immunity to larval infection in mice. This dogma is entrenched notwithstanding the numerous re‐ ports documenting the importance of exclusive type 2 immune responses in rat, monkey, and human schistosomiasis, and despite that larval antigens induce principally Th1 relat‐

ed cytokines and antibodies that are not entirely protective in mice. Enhancement of these Th1 responses during mouse immunization, via the use of Th1-biased constructs and adjuvants, consistently elicited only partial resistance, with candidate vaccine anti‐ gens discarded one after the other.

characterized by granulomas formation around the eggs and progressive liver (*S. mansoni*) or urinary bladder (*S*. *haematobium*) tissue damage and fibrosis [21], and dominated by Th2

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

181

Skewing of the immune responses of patently infected hosts towards the Th2 axis may be the reason whereby infection with schistosomes increases the severity of subsequent infec‐ tion with other pathogens namely *Plasmodium falciparum*, *Leishmania*, *Toxoplasma gondii*, *My‐ cobacteria*, *Entamoeba histolytica*, *Staphylococcus aureus*, or *Salmonella* [22, and references therein]. Schistosomiasis also may predispose individuals to infection with human immuno‐ deficiency (HIV) and hepatitis C (HCV) virus, and increases resulting disease persistence and severity [2,23,24]. Individuals with schistosomiasis haematobium are at great risk for HIV infection, and for cancer development [24,25], afflictions all requiring robust Th1 re‐

Schistosome species require 2 hosts, a definitive mammalian and an intermediate freshwater snail host, for completion of the life cycle. *Schistosoma mansoni* and *S. haematobium* eggs re‐ lease the miracidium, which must find a snail of the genus *Biomphalaria* and *Bulinus*, respec‐ tively for asexual reproduction, whereby infection of a compatible snail with a single miracidium results in production of thousands of infective cercariae [12,20]. The prevalence of schistosomiasis is linked to compatible snail distribution. Accordingly, breaking the dreadful cycle may well be accomplished via elimination of the obligatory intermediate

Snails of the *Biomphalaria* and *Bulinus* spp. live under water, and all molluscicidal measures must take into account vegetation, fish, ducks, and other animals habitat, as well as water quality for drinking and irrigation, rendering control of snails with chemicals, such as acro‐

People acquire schistosomiasis while farming, fishing, bathing, washing, and performing recreational activities in the vicinity of water bodies contaminated with infected snails. Ac‐ cordingly, safe water supply, improved sanitation, and health education are mandatory in order to effectively reduce (and eventually eliminate) the very significant global burden of disease due to schistosomiasis and other helminthic parasites, yet are unavailable in numer‐

Praziquantel (PZQ), a pyrazino-isoquinoline derivative, FW 312.41, is practically now the single cost-affordable, and relatively safe and effective oral drug for mass treatment of hun‐ dreds of millions of individuals afflicted with schistosomiasis mansoni, schistosomiasis hae‐

lein, copper sulfate, and niclosamide, a particularly costly approach [2,27].

ous countries due to poor economical, social, and political conditions [2-4].

cytokines [14,15].

**2.2. Control**

snail host.

*2.2.3. Praziquantel*

*2.2.1. Molluscicides*

sponses for control and elimination [26].

*2.2.2. Sanitation and health education*

This review aims to dispel these dogmas and opens a new avenue for the development of a remedy and vaccine for schistosomiasis.

## **2. Body**

#### **2.1. Schistosomiasis**

Schistosomiasis, also known as bilharziosis, bilharzia, or snail fever, is endemic in 74 coun‐ tries of the Developing World, infecting between 391 and 600 million people worldwide. with close to 800 million, mostly children, at risk [2,3]. The disease burden is estimated to exceed 70 million disability-adjusted life-years [4]. The causative agents are flatworms, dioe‐ cious (separate sex) trematodes, of the family Schistosomatidae, with *Schistosoma mansoni* and *Schistosoma haematobium* responsible for the largest numbers of human infections. The infective stage, the cercaria, invades host skin, and stays in the blood- and lymph-free epi‐ dermis for a minimum of 40 and up to 72 hr, impervious to innate immunity effectors [5,6]. The parasite develops into a schistosomulum, exchanging the classical outer membrane for a double lipid bilayer covering [7], and releasing in the process of physiological and biochemi‐ cal changes numerous enzymes and other molecules, which may interact with the innate im‐ munity receptors on keratinocytes and Langerhans cells [4,8-11]. The innate immunity cells proceed to activation of the acquired immune system, and produce cytokines that shape the amount and direction of the adaptive immune responses to the developing parasite [4,8-10]. Schistosomula then penetrate dermal blood vessels, and remain intravascular for their life span, and therefore, schistosomes of the genus *Schistosoma* are known as blood flukes [12]. The schistosomula travel via the pulmonary artery reaching the lungs within 4-6 and 6-10 days for *S. mansoni* and *S. haematobium*, respectively [13], painstakingly negociate the lung capillaries, then migrate to the hepatic portal vessels, where they start to actively feed, ma‐ ture, and copulate. It is important here to recall that developing (and mature) schistosomes live in the blood vessels and capillaries, and hence, released, excreted, or secreted molecules are blood-borne products, which likely access macrophages, dendritic cells, and B cells in the spleen rather than the lung tissue draining lymph nodes. It is documented that develop‐ ing schistosomula products elicit predominant T helper (Th) Th1 and Th17 immune re‐ sponses, dominated by interferon-gamma (IFN-g) and interleukin (IL)-17, and IgG2a and IgG2b antibodies [14-19]. The male carrying the female in the gynaecophoric groove, the schist, then migrates to the mesenteric venules (*S. mansoni*) or the vesical capillaries around the urinary bladder (*S*. *haematobium*). Hundreds of eggs are deposited daily. Eggs exit the host via the intestine with the feces (*S. mansoni*) or the urinary bladder, with the urine (*S. haematobium*) to continue the life cycle in compatible snails [12,20]. Numerous eggs are re‐ tained in the host tissue, inciting intense immune responses to the parasite egg antigens, characterized by granulomas formation around the eggs and progressive liver (*S. mansoni*) or urinary bladder (*S*. *haematobium*) tissue damage and fibrosis [21], and dominated by Th2 cytokines [14,15].

Skewing of the immune responses of patently infected hosts towards the Th2 axis may be the reason whereby infection with schistosomes increases the severity of subsequent infec‐ tion with other pathogens namely *Plasmodium falciparum*, *Leishmania*, *Toxoplasma gondii*, *My‐ cobacteria*, *Entamoeba histolytica*, *Staphylococcus aureus*, or *Salmonella* [22, and references therein]. Schistosomiasis also may predispose individuals to infection with human immuno‐ deficiency (HIV) and hepatitis C (HCV) virus, and increases resulting disease persistence and severity [2,23,24]. Individuals with schistosomiasis haematobium are at great risk for HIV infection, and for cancer development [24,25], afflictions all requiring robust Th1 re‐ sponses for control and elimination [26].

## **2.2. Control**

ed cytokines and antibodies that are not entirely protective in mice. Enhancement of these Th1 responses during mouse immunization, via the use of Th1-biased constructs and adjuvants, consistently elicited only partial resistance, with candidate vaccine anti‐

This review aims to dispel these dogmas and opens a new avenue for the development of a

Schistosomiasis, also known as bilharziosis, bilharzia, or snail fever, is endemic in 74 coun‐ tries of the Developing World, infecting between 391 and 600 million people worldwide. with close to 800 million, mostly children, at risk [2,3]. The disease burden is estimated to exceed 70 million disability-adjusted life-years [4]. The causative agents are flatworms, dioe‐ cious (separate sex) trematodes, of the family Schistosomatidae, with *Schistosoma mansoni* and *Schistosoma haematobium* responsible for the largest numbers of human infections. The infective stage, the cercaria, invades host skin, and stays in the blood- and lymph-free epi‐ dermis for a minimum of 40 and up to 72 hr, impervious to innate immunity effectors [5,6]. The parasite develops into a schistosomulum, exchanging the classical outer membrane for a double lipid bilayer covering [7], and releasing in the process of physiological and biochemi‐ cal changes numerous enzymes and other molecules, which may interact with the innate im‐ munity receptors on keratinocytes and Langerhans cells [4,8-11]. The innate immunity cells proceed to activation of the acquired immune system, and produce cytokines that shape the amount and direction of the adaptive immune responses to the developing parasite [4,8-10]. Schistosomula then penetrate dermal blood vessels, and remain intravascular for their life span, and therefore, schistosomes of the genus *Schistosoma* are known as blood flukes [12]. The schistosomula travel via the pulmonary artery reaching the lungs within 4-6 and 6-10 days for *S. mansoni* and *S. haematobium*, respectively [13], painstakingly negociate the lung capillaries, then migrate to the hepatic portal vessels, where they start to actively feed, ma‐ ture, and copulate. It is important here to recall that developing (and mature) schistosomes live in the blood vessels and capillaries, and hence, released, excreted, or secreted molecules are blood-borne products, which likely access macrophages, dendritic cells, and B cells in the spleen rather than the lung tissue draining lymph nodes. It is documented that develop‐ ing schistosomula products elicit predominant T helper (Th) Th1 and Th17 immune re‐ sponses, dominated by interferon-gamma (IFN-g) and interleukin (IL)-17, and IgG2a and IgG2b antibodies [14-19]. The male carrying the female in the gynaecophoric groove, the schist, then migrates to the mesenteric venules (*S. mansoni*) or the vesical capillaries around the urinary bladder (*S*. *haematobium*). Hundreds of eggs are deposited daily. Eggs exit the host via the intestine with the feces (*S. mansoni*) or the urinary bladder, with the urine (*S. haematobium*) to continue the life cycle in compatible snails [12,20]. Numerous eggs are re‐ tained in the host tissue, inciting intense immune responses to the parasite egg antigens,

gens discarded one after the other.

**2. Body**

**2.1. Schistosomiasis**

180 Parasitic Diseases - Schistosomiasis

remedy and vaccine for schistosomiasis.

## *2.2.1. Molluscicides*

Schistosome species require 2 hosts, a definitive mammalian and an intermediate freshwater snail host, for completion of the life cycle. *Schistosoma mansoni* and *S. haematobium* eggs re‐ lease the miracidium, which must find a snail of the genus *Biomphalaria* and *Bulinus*, respec‐ tively for asexual reproduction, whereby infection of a compatible snail with a single miracidium results in production of thousands of infective cercariae [12,20]. The prevalence of schistosomiasis is linked to compatible snail distribution. Accordingly, breaking the dreadful cycle may well be accomplished via elimination of the obligatory intermediate snail host.

Snails of the *Biomphalaria* and *Bulinus* spp. live under water, and all molluscicidal measures must take into account vegetation, fish, ducks, and other animals habitat, as well as water quality for drinking and irrigation, rendering control of snails with chemicals, such as acro‐ lein, copper sulfate, and niclosamide, a particularly costly approach [2,27].

## *2.2.2. Sanitation and health education*

People acquire schistosomiasis while farming, fishing, bathing, washing, and performing recreational activities in the vicinity of water bodies contaminated with infected snails. Ac‐ cordingly, safe water supply, improved sanitation, and health education are mandatory in order to effectively reduce (and eventually eliminate) the very significant global burden of disease due to schistosomiasis and other helminthic parasites, yet are unavailable in numer‐ ous countries due to poor economical, social, and political conditions [2-4].

#### *2.2.3. Praziquantel*

Praziquantel (PZQ), a pyrazino-isoquinoline derivative, FW 312.41, is practically now the single cost-affordable, and relatively safe and effective oral drug for mass treatment of hun‐ dreds of millions of individuals afflicted with schistosomiasis mansoni, schistosomiasis hae‐ matobium, and schistosomiasis japonicum as well [2-4,21]. Due to its hydrophobic nature and small size, PZQ inserts itself into the parasite outer lipid bilayer membrane, leading to its vacuolization, blebbing, and disruption [28]. Several reports documented the ability of PZQ to bind and polymerise actin [29-34]. Actin-based membrane skeleton (the fence) lies beneath the inner leaflet of the plasma membrane [35], and accordingly PZQ-parasite actin binding and subsequent polymerization may explain the severe muscle contraction and the paralysis worms undergo immediately upon exposure in vitro to PZQ. This mode of action, if proven to be true, suggests that PZQ treatment might not be entirely safe for children, per‐ sons with cardiovascular afflictions, and pregnant women [36].

over two independent trials in CBA/CaH mice [65]. The protection levels were not repro‐ duced using *S. japonicum* counterpart, whereby mice immunized with the recombinant pro‐ tein of a single TSP-2 subclass showed no protection, while immunization with a mixture of seven recombinant TSP-2 subclasses provided a moderate protection [66]. A recent study used *S. mansoni* TSP-2 extracellular loop 2 region in conjunction with alum and CpG as adju‐ vants leading to extremely variable protection levels against challenge infection within co‐ horts of highly inbred C57BL/6 mice [67]. An *S. mansoni* stomatin-like protein, a tegument protein located at the host-parasite interface, engendered in immunized mice a partial pro‐ tection of 30-32%, associated with specific IgG1 and IgG2a antibodies and elevated produc‐ tion of IFN-g and tumor necrosis factor (TNF), while no IL-4 production was detected, suggesting a Th1-predominant immune response [68]. A schistosomular tegument prepara‐ tion (Smteg) was used for C57BL/6 mice immunization, subcutaneously, on days 0, 15, and 30, resulting in significant antibody production, increased percentage of CD4 + IFN-g+ and CD4 + IL-10+ cells in spleen and increased production of IFN-g and IL-10 by spleen cells, but

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

183

Sm23-, tetraspanins-, and other tegument-associated molecules- based protection was ascri‐ bed to specific antibody interaction with the molecules residing at the host-parasite inter‐ face, followed by binding to effector cells, which are able to elicit vigorous complement, and antibody-dependent cell-mediated cytotoxicity (ADCC) [65,67]. Indeed, ADCC was shown to be effective in killing a substantial proportion of 3-, 18- and sometimes 24-hr-old schisto‐ somula [70-76], a phenomenon of limited in vivo relevance since larvae of that age still re‐ side in the epidermis, impervious to any immune attack. On the other hand, older larvae, migrating schistosomula, pre-adut and adult worms surface membrane antigens are inacces‐ sible to antibody binding [77,78], and thus, not threatened by ADCC. According, surface membrane, like cytosolic, antigens may not be considered for effective vaccination against

No vaccine antigens appeared available, while we were striken by the paradox of lung-stage schistosomula being documented as the target of innate and RA vaccine immunity [1,40], and obtaining nutrients essentially via the tegument, while their surface membrane are en‐

**3.1. Lung-stage schistosomula strive without feeding in lung capillaries while surface membrane molecules are entirely hidden, inaccessible to specific antibody binding**

Migrating schistosomula usually do not ingest erythrocytes because of their undersized mouth [79], and import sugar, fatty acids, and other nutrients directly across their tegument and into their internal tissues via membrane-spanning transporters [80-82]. Paradoxically, no specific antibody is able to bind to lung-stage larvae surface membrane antigens, as judged by several serological tests, namely indirect membrane immunofluorescence [1,40,77,78,83-89]. We were unable to visualize the presence of the glucose transporter

failed to reduce parasite burden, female fecundity and morbidity [69].

tirely hidden, inaccessible to specific antibody binding.

**3. The enigma of the lung-stage schistosomula**

schistosome infection.

Even if absolutely and entirely safe, PZQ treatment is not 100% proof and does not prevent reinfection or diminishes prevalence [37], necessitating periodic examination and repeated treatments, and thus, exacerbating the possiblity of the emergence of parasite resistance to the drug, a threat that has already materialized in several settings [38,39].

#### *2.2.4. Vaccine status − Documented target: The lung-stage schistosomula*

The hope for development of a schistosomiasis vaccine stems from the strong, and reprodu‐ cible, protective immunity obtained after immunization of experimental hosts with radia‐ tion-attenuated (RA) cercariae [1,40], and the documented human resistance to infection (endemic normals), or reinfection after chemotherapy [41-43]. Sera and spleen cells of RAvaccinated, and worm antigens-protectively immunized mice were used for identification of the potential protective target antigens. These studies resulted in identification, cloning, gene expression and assessment of protective potential of a plethora of molecules, among which *S. mansoni* irradiation associated vaccine antigen, IrV-5 [44], glutathione-S-transferase, GST [45], triose phosphate isomerase, TPI [46,47], paramyosin [48], fatty acid binding pro‐ tein, Sm 14 [49], the surface membrane antigen Sm23 [50], the calcium-dependent cysteine protease, calpain [51], enolase [52,53], and calreticulin [54-56]. Reactivity of serum antibodies and peripheral blood mononuclear cells of resistant humans with fractionated worm mole‐ cules succeeded in identification of *S. mansoni* glyceraldehyde 3-phosphate dehydrogenase [57-61] as a potential candidate vaccine antigen. These molecules were used in conjunction with different adjuvants, namely complete (CFA) and incomplete (IFA) Freund's adjuvant for mouse immunization, leading to only hardly significant (*P* < 0.05) of some 30-35% reduc‐ tion of challenge worm burden. Except for Sm23, these molecules are all cytosolic, and the poor protective capacity was ascribed to their inability to interact with the host immune sys‐ tem effector molecules.

Sm 23, an outer *S. mansoni* surface membrane antigen was among the molecules thought to be a target of protective immunity and of potential importance due to its residence at the host-parasite interface [50]. The full length molecule in a plasmid or recombinant form failed to lead to highly significant, consistent, or reproducible protection despite of their use in combination with a number of different adjuvants [62-64]. The *S. mansoni* integral surface membrane proteins tetraspanins (TSP)-1 and TSP-2 encoding cDNA were cloned, se‐ quenced, and expressed and shown to elicit protection levels of 57% and 64% (TSP-2) and 34% and 52% (TSP-1) for mean adult worm burdens and liver egg burdens, respectively, over two independent trials in CBA/CaH mice [65]. The protection levels were not repro‐ duced using *S. japonicum* counterpart, whereby mice immunized with the recombinant pro‐ tein of a single TSP-2 subclass showed no protection, while immunization with a mixture of seven recombinant TSP-2 subclasses provided a moderate protection [66]. A recent study used *S. mansoni* TSP-2 extracellular loop 2 region in conjunction with alum and CpG as adju‐ vants leading to extremely variable protection levels against challenge infection within co‐ horts of highly inbred C57BL/6 mice [67]. An *S. mansoni* stomatin-like protein, a tegument protein located at the host-parasite interface, engendered in immunized mice a partial pro‐ tection of 30-32%, associated with specific IgG1 and IgG2a antibodies and elevated produc‐ tion of IFN-g and tumor necrosis factor (TNF), while no IL-4 production was detected, suggesting a Th1-predominant immune response [68]. A schistosomular tegument prepara‐ tion (Smteg) was used for C57BL/6 mice immunization, subcutaneously, on days 0, 15, and 30, resulting in significant antibody production, increased percentage of CD4 + IFN-g+ and CD4 + IL-10+ cells in spleen and increased production of IFN-g and IL-10 by spleen cells, but failed to reduce parasite burden, female fecundity and morbidity [69].

Sm23-, tetraspanins-, and other tegument-associated molecules- based protection was ascri‐ bed to specific antibody interaction with the molecules residing at the host-parasite inter‐ face, followed by binding to effector cells, which are able to elicit vigorous complement, and antibody-dependent cell-mediated cytotoxicity (ADCC) [65,67]. Indeed, ADCC was shown to be effective in killing a substantial proportion of 3-, 18- and sometimes 24-hr-old schisto‐ somula [70-76], a phenomenon of limited in vivo relevance since larvae of that age still re‐ side in the epidermis, impervious to any immune attack. On the other hand, older larvae, migrating schistosomula, pre-adut and adult worms surface membrane antigens are inacces‐ sible to antibody binding [77,78], and thus, not threatened by ADCC. According, surface membrane, like cytosolic, antigens may not be considered for effective vaccination against schistosome infection.

No vaccine antigens appeared available, while we were striken by the paradox of lung-stage schistosomula being documented as the target of innate and RA vaccine immunity [1,40], and obtaining nutrients essentially via the tegument, while their surface membrane are en‐ tirely hidden, inaccessible to specific antibody binding.

## **3. The enigma of the lung-stage schistosomula**

matobium, and schistosomiasis japonicum as well [2-4,21]. Due to its hydrophobic nature and small size, PZQ inserts itself into the parasite outer lipid bilayer membrane, leading to its vacuolization, blebbing, and disruption [28]. Several reports documented the ability of PZQ to bind and polymerise actin [29-34]. Actin-based membrane skeleton (the fence) lies beneath the inner leaflet of the plasma membrane [35], and accordingly PZQ-parasite actin binding and subsequent polymerization may explain the severe muscle contraction and the paralysis worms undergo immediately upon exposure in vitro to PZQ. This mode of action, if proven to be true, suggests that PZQ treatment might not be entirely safe for children, per‐

Even if absolutely and entirely safe, PZQ treatment is not 100% proof and does not prevent reinfection or diminishes prevalence [37], necessitating periodic examination and repeated treatments, and thus, exacerbating the possiblity of the emergence of parasite resistance to

The hope for development of a schistosomiasis vaccine stems from the strong, and reprodu‐ cible, protective immunity obtained after immunization of experimental hosts with radia‐ tion-attenuated (RA) cercariae [1,40], and the documented human resistance to infection (endemic normals), or reinfection after chemotherapy [41-43]. Sera and spleen cells of RAvaccinated, and worm antigens-protectively immunized mice were used for identification of the potential protective target antigens. These studies resulted in identification, cloning, gene expression and assessment of protective potential of a plethora of molecules, among which *S. mansoni* irradiation associated vaccine antigen, IrV-5 [44], glutathione-S-transferase, GST [45], triose phosphate isomerase, TPI [46,47], paramyosin [48], fatty acid binding pro‐ tein, Sm 14 [49], the surface membrane antigen Sm23 [50], the calcium-dependent cysteine protease, calpain [51], enolase [52,53], and calreticulin [54-56]. Reactivity of serum antibodies and peripheral blood mononuclear cells of resistant humans with fractionated worm mole‐ cules succeeded in identification of *S. mansoni* glyceraldehyde 3-phosphate dehydrogenase [57-61] as a potential candidate vaccine antigen. These molecules were used in conjunction with different adjuvants, namely complete (CFA) and incomplete (IFA) Freund's adjuvant for mouse immunization, leading to only hardly significant (*P* < 0.05) of some 30-35% reduc‐ tion of challenge worm burden. Except for Sm23, these molecules are all cytosolic, and the poor protective capacity was ascribed to their inability to interact with the host immune sys‐

Sm 23, an outer *S. mansoni* surface membrane antigen was among the molecules thought to be a target of protective immunity and of potential importance due to its residence at the host-parasite interface [50]. The full length molecule in a plasmid or recombinant form failed to lead to highly significant, consistent, or reproducible protection despite of their use in combination with a number of different adjuvants [62-64]. The *S. mansoni* integral surface membrane proteins tetraspanins (TSP)-1 and TSP-2 encoding cDNA were cloned, se‐ quenced, and expressed and shown to elicit protection levels of 57% and 64% (TSP-2) and 34% and 52% (TSP-1) for mean adult worm burdens and liver egg burdens, respectively,

sons with cardiovascular afflictions, and pregnant women [36].

the drug, a threat that has already materialized in several settings [38,39].

*2.2.4. Vaccine status − Documented target: The lung-stage schistosomula*

tem effector molecules.

182 Parasitic Diseases - Schistosomiasis

### **3.1. Lung-stage schistosomula strive without feeding in lung capillaries while surface membrane molecules are entirely hidden, inaccessible to specific antibody binding**

Migrating schistosomula usually do not ingest erythrocytes because of their undersized mouth [79], and import sugar, fatty acids, and other nutrients directly across their tegument and into their internal tissues via membrane-spanning transporters [80-82]. Paradoxically, no specific antibody is able to bind to lung-stage larvae surface membrane antigens, as judged by several serological tests, namely indirect membrane immunofluorescence [1,40,77,78,83-89]. We were unable to visualize the presence of the glucose transporter SGTP4 on the surface membrane of intact in vitro cultured or ex vivo 5 -7 day-old schistoso‐ mula, using specific antibodies and indirect membrane immunofluorescence [90]. Entire fail‐ ure of larval surface membrane antigen detection does not give support to the contention that the tegument is bounded externally by a single lipid bilayer, overlain by a laminate se‐ cretion containing numerous proteins and molecular complexes [82,91], and was previously ascribed to shedding of antigenic molecules [86], masking by host proteins [85,88], or intrin‐ sic biochemical modifications of the outer membrane [77,83,84,87, 89].

by staining with filipin III, a fluorescent polyene antibiotic, widely used for the detection and the quantitation of cholesterol in biomembranes, allowed us to examine the role of cho‐ lesterol in surface membrane antigen sequestration of *S. mansoni* and *S*. *haematobium* ex vivo lung-stage larvae. Evaluation of cholesterol content and distribution by filipin staining dem‐ onstrated that MBCD efficiently extracts cholesterol from the surface membrane of *S. manso‐ ni* and *S*. *haematobium* lung-stage larvae [93,94]. Treatment of *S. mansoni* ex-vivo lung-stage larvae with MBCD consistently and reproducibly led to considerable binding of specific an‐ tibodies to the outer membrane surface. The data, thus, suggest that depletion of cholesterol from the outer membrane of *S. mansoni* lung-stage schistosomula corrects their failure to bind antibodies in the fluorescent antibody test. However, *S. haematobium* larvae treated with 2.5, 5.0, or 10 mM MBCD were consistently negative following incubation with either control or RA serum in the fluorescent antibody test. Hence, the results indicated that al‐ most complete depletion of cholesterol from the surface membrane of *S. haematobium* larvae did not modify the negligible binding of specific antibodies by the surface membrane anti‐ gens. This means that *S. haematobium* and *S. mansoni* ex vivo lung-stage larvae differ regard‐ ing the contribution of cholesterol to the sequestration of surface membrane antigens [93,94].

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

185

**3.3. Solving the schistosomula lung-stage enigma and predicting the existence of a**

ed FA concentrations and shorter incubation periods [95, and references therein].

bodies [95,96].

Evaluation of cholesterol amount and distribution by the filipin staining method indicated that unsaturated FA did not appear to elicit exposure of schistosomular surface membrane antigens via cholesterol extraction, as previously suggested. While a definite proof needs and remains to be established, some lines of evidence support the hypothesis that unsaturat‐ ed FA might elicit larval surface membrane antigen exposure via their ability to stimulate a putative tegument-associated nSMase, with subsequent SM hydrolysis, and access of anti‐

We have been able to demonstrate that 1- intact healthy ex vivo schistosomula, display‐ ing equilibrium in SM synthesis and hydrolysis, allow molecules of less than 600 Da to access their surface membrane molecules. 2- Ex vivo larvae exposed to conditions condu‐

The data together strongly supported the contention that antigenic molecules persist on the surface of ex-vivo lung-stage schistosomula [89-91], yet are entirely inaccessible to specific antibody binding, in part due to cholesterol sequestration. Surface membrane antigens of *S. mansoni* and *S. haematobium* ex vivo lung schistosomula were, however, readily exposed to specific antibody binding following incubation in corn oil as mentioned above. It was hy‐ pothesized that corn oil unsaturated fatty acids (FA) might activate parasite surface mem‐ brane-bound neutral sphingomyelinase (nSMase), leading to hydrolysis of surface membrane sphingomyelin (SM), and subsequent decrease in outer bilayer lipid rigidity and permeability. At variance from MBCD, incubation of lung-stage schistosomula with unsatu‐ rated FA, such as corn and olive oil, or arachidonic acid (ARA), led to exposure of the, other‐ wise concealed, surface membrane antigens of *S. mansoni* and *S. haematobium* alike. In that respect, *S. haematobium* appeared more sensitive than *S. mansoni*, requiring lower unsaturat‐

**parasite tegument-associated neutral sphingomyelinase (nSMase)**

#### **3.2. Attempts to expose the lung-stage and adult worm surface membrane antigens to specific antibody binding**

In an attempt to overcome the lack of exposure of *S. mansoni* and *S. haematobium* lung stage larvae apical membrane antigens to specific antibody binding, we started by manipulating potential cues for increased surface antigenic expression, such as lack of glucose and amino acids, and extremes of pH or HCO3 concentration. All such trials failed to alter the negligi‐ ble *S. mansoni* larval reactivity with RA vaccine and infection sera in membrane indirect im‐ munofluorescence (IF). It was then thought that incubation of ex-vivo lung stage schistosomula in strongly hydrophobic medium might induce exposure of outer surface membrane hydrophobic sites, where antigenic molecules could be sequestered. Lung-stage schistosomula were, therefore, incubated with sera diluted in sterile corn oil. It is of note that corn oil essentially consists of poly- (linoleic acid, 45.9 to 55.5 %), and mono- (olecic acid, 28.4 to 36.9 %) unsaturated fatty acids, and contains 1 to 2% unsaponifiables particular‐ ly rich in sterols and tocopherols. *Schistosoma mansoni* [92] and *S. haematobium* (Figure 1) exvivo lung-stage schistosomula could readily bind specific antibodies of RA vaccine or infection sera in the fluorescent antibody test, following incubation in corn-oil in a concen‐ tration- and time-dependent manner.

**Figure 1.** Assessment of the serological reactivity of *S. haematobium* lung-stage schistosomula by IF. Seven days ex vivo larvae incubated with control (A,C) or RA vaccine (B,D) serum diluted 1:50 in RPMI medium, before (A,B) or fol‐ lowing incubation for 6 hr with 90% oil (C,D) were tested in IF and photographed under ultraviolet microscopy. x 200.

Since incubation of lung-stage parasites in corn oil led to exposure of antigenic sites in a con‐ centration and time-dependent fashion, it was suggested that corn oil lipids may mediate ef‐ flux of cholesterol or phospholipids from the worm outer membrane, leading to changes in lateral diffusion of surface antigens that resulted into a dramatic increase in the avidity of antibody binding. Treatment with the membrane-impermeable, cholesterol-extracting drug methyl-b-cyclodextrin (MBCD), followed by visualization of surface membrane cholesterol by staining with filipin III, a fluorescent polyene antibiotic, widely used for the detection and the quantitation of cholesterol in biomembranes, allowed us to examine the role of cho‐ lesterol in surface membrane antigen sequestration of *S. mansoni* and *S*. *haematobium* ex vivo lung-stage larvae. Evaluation of cholesterol content and distribution by filipin staining dem‐ onstrated that MBCD efficiently extracts cholesterol from the surface membrane of *S. manso‐ ni* and *S*. *haematobium* lung-stage larvae [93,94]. Treatment of *S. mansoni* ex-vivo lung-stage larvae with MBCD consistently and reproducibly led to considerable binding of specific an‐ tibodies to the outer membrane surface. The data, thus, suggest that depletion of cholesterol from the outer membrane of *S. mansoni* lung-stage schistosomula corrects their failure to bind antibodies in the fluorescent antibody test. However, *S. haematobium* larvae treated with 2.5, 5.0, or 10 mM MBCD were consistently negative following incubation with either control or RA serum in the fluorescent antibody test. Hence, the results indicated that al‐ most complete depletion of cholesterol from the surface membrane of *S. haematobium* larvae did not modify the negligible binding of specific antibodies by the surface membrane anti‐ gens. This means that *S. haematobium* and *S. mansoni* ex vivo lung-stage larvae differ regard‐ ing the contribution of cholesterol to the sequestration of surface membrane antigens [93,94].

SGTP4 on the surface membrane of intact in vitro cultured or ex vivo 5 -7 day-old schistoso‐ mula, using specific antibodies and indirect membrane immunofluorescence [90]. Entire fail‐ ure of larval surface membrane antigen detection does not give support to the contention that the tegument is bounded externally by a single lipid bilayer, overlain by a laminate se‐ cretion containing numerous proteins and molecular complexes [82,91], and was previously ascribed to shedding of antigenic molecules [86], masking by host proteins [85,88], or intrin‐

**3.2. Attempts to expose the lung-stage and adult worm surface membrane antigens to**

In an attempt to overcome the lack of exposure of *S. mansoni* and *S. haematobium* lung stage larvae apical membrane antigens to specific antibody binding, we started by manipulating potential cues for increased surface antigenic expression, such as lack of glucose and amino

ble *S. mansoni* larval reactivity with RA vaccine and infection sera in membrane indirect im‐ munofluorescence (IF). It was then thought that incubation of ex-vivo lung stage schistosomula in strongly hydrophobic medium might induce exposure of outer surface membrane hydrophobic sites, where antigenic molecules could be sequestered. Lung-stage schistosomula were, therefore, incubated with sera diluted in sterile corn oil. It is of note that corn oil essentially consists of poly- (linoleic acid, 45.9 to 55.5 %), and mono- (olecic acid, 28.4 to 36.9 %) unsaturated fatty acids, and contains 1 to 2% unsaponifiables particular‐ ly rich in sterols and tocopherols. *Schistosoma mansoni* [92] and *S. haematobium* (Figure 1) exvivo lung-stage schistosomula could readily bind specific antibodies of RA vaccine or infection sera in the fluorescent antibody test, following incubation in corn-oil in a concen‐

A B C D

**Figure 1.** Assessment of the serological reactivity of *S. haematobium* lung-stage schistosomula by IF. Seven days ex vivo larvae incubated with control (A,C) or RA vaccine (B,D) serum diluted 1:50 in RPMI medium, before (A,B) or fol‐ lowing incubation for 6 hr with 90% oil (C,D) were tested in IF and photographed under ultraviolet microscopy. x 200.

Since incubation of lung-stage parasites in corn oil led to exposure of antigenic sites in a con‐ centration and time-dependent fashion, it was suggested that corn oil lipids may mediate ef‐ flux of cholesterol or phospholipids from the worm outer membrane, leading to changes in lateral diffusion of surface antigens that resulted into a dramatic increase in the avidity of antibody binding. Treatment with the membrane-impermeable, cholesterol-extracting drug methyl-b-cyclodextrin (MBCD), followed by visualization of surface membrane cholesterol

concentration. All such trials failed to alter the negligi‐

sic biochemical modifications of the outer membrane [77,83,84,87, 89].


**specific antibody binding**

184 Parasitic Diseases - Schistosomiasis

acids, and extremes of pH or HCO3

tration- and time-dependent manner.

#### **3.3. Solving the schistosomula lung-stage enigma and predicting the existence of a parasite tegument-associated neutral sphingomyelinase (nSMase)**

The data together strongly supported the contention that antigenic molecules persist on the surface of ex-vivo lung-stage schistosomula [89-91], yet are entirely inaccessible to specific antibody binding, in part due to cholesterol sequestration. Surface membrane antigens of *S. mansoni* and *S. haematobium* ex vivo lung schistosomula were, however, readily exposed to specific antibody binding following incubation in corn oil as mentioned above. It was hy‐ pothesized that corn oil unsaturated fatty acids (FA) might activate parasite surface mem‐ brane-bound neutral sphingomyelinase (nSMase), leading to hydrolysis of surface membrane sphingomyelin (SM), and subsequent decrease in outer bilayer lipid rigidity and permeability. At variance from MBCD, incubation of lung-stage schistosomula with unsatu‐ rated FA, such as corn and olive oil, or arachidonic acid (ARA), led to exposure of the, other‐ wise concealed, surface membrane antigens of *S. mansoni* and *S. haematobium* alike. In that respect, *S. haematobium* appeared more sensitive than *S. mansoni*, requiring lower unsaturat‐ ed FA concentrations and shorter incubation periods [95, and references therein].

Evaluation of cholesterol amount and distribution by the filipin staining method indicated that unsaturated FA did not appear to elicit exposure of schistosomular surface membrane antigens via cholesterol extraction, as previously suggested. While a definite proof needs and remains to be established, some lines of evidence support the hypothesis that unsaturat‐ ed FA might elicit larval surface membrane antigen exposure via their ability to stimulate a putative tegument-associated nSMase, with subsequent SM hydrolysis, and access of anti‐ bodies [95,96].

We have been able to demonstrate that 1- intact healthy ex vivo schistosomula, display‐ ing equilibrium in SM synthesis and hydrolysis, allow molecules of less than 600 Da to access their surface membrane molecules. 2- Ex vivo larvae exposed to conditions condu‐ cive to nSMase inactivation (pH less than 7.2, high concentrations of nitric oxide or hy‐ drogen peroxide), do not allow neither antibodies nor even very small molecules (less than 600 Da) to access their surface membrane molecules [96]. Sphingomyelin appears critical in maintaining the rigidity and impermeability of the parasite outer lipid bilayer, likely via the ability of hydroxyl and amide groups in the interfacial region of sphingoli‐ pids to form with water molecules a tight netwok of hydrogen bonds [96, and references therein]. Recently, quasi-elastic and inelastic neutron scattering experiments on *S. manso‐ ni* and *S. haematobium* worms and larvae have been performed. The obtained experimen‐ tal findings suggest that the larva-medium interaction is triggered by the hydrogen bond network. Furthermore, the strength of that hydrogen bond network-based interaction ap‐ peared to be higher for *S. mansoni* larvae than adult worms and for *S. mansoni* than *S. haematobium* [Federica Migliardo, Unpublished Observations]. 3- Inhibition of ex vivo lar‐ vae SM synthesis or moderate nSMase activation (exposure to low concentrations of un‐ saturated FA, especially ARA) allows specific antibody access and visualization of surface membrane antigens. Exposure of ex vivo larvae to conditions conducive to exces‐ sive nSMase activation (hypoxia, high concentrations of unsaturated FA, notably ARA) lead to their irreversible attrition [96, and references therein].

#### **3.4. Evidence for the existence of parasite tegument-associated nSMase and its activation by arachidonic acid**

**Figure 2.** Homology between predicted amino acid sequences of *S. mansoni* (SMnSM) and *S*. *haematobium* (SHnSM)

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

187

A systematically improved high quality genome and transcriptome of the human blood fluke *S. mansoni* was recently reported by Protasio et al. (unpublished observations), where‐ by sequence for *S. mansoni* putative nSMase was now shown to encode 431 (CCD60196.1) and not 631 (XP\_002578732.1) aa and 100% identity with the latter sequence only for the first 345 aa, as only 2 transmembrane domains were identified near the carboxyl end, between aa

It is of note that the whole-genome sequence of *S*. *haematobium* was recently published [99], and reported the coding sequence (1038 bp) of an *S. haematobium* putative neutral sphingo‐ myelinase (http://www.schistodb.net; Sha\_103241), encoding 345 aa, with 3 transmembrane domains at the carboxyl end. Blasting of our SHnSM sequences with Sha\_103241 revealed 94-97% homology. However, the sretch of SHnSm aa33-116 (highlighted in Figure 2), which contained EEP superfamily signature sites and showed complete homology with the *S. man‐*

Antibodies specific to *S. mansoni* nSMase were generated in mice, immunized with peptides based on the molecule predicted aa sequence, synthesized as multiple antigen peptide (MAP) constructs. We were able to confirm the presence of the enzyme in adult male and female *S. mansoni* and *S*. *haematobium* tegument as judged by enzyme-linked immunosorb‐ ent assay (ELISA) and membrane and cytoplasmic IF. We were also the first to measure nSMase enzymatic activity in Triton X-100-solubilized surface membrane (Sup 1) and whole worm soluble (SWAP) molecules of male and female *S. mansoni* and *S. haematobium*. Neutral, but no acidic, sphingomyelinase activity was readily detectable by the Amplex Red Sphin‐ gomyelinase Assay, and increased with incubation time and protein amount. The nSMase

*soni* counterpart, was lacking in Sha\_103241 published sequence.

neutral sphingomyelinase.

325 and 375.

In 2006, we predicted, and provided evidence for, the existence of a schistosome tegu‐ ment-associated Mg2+-dependent nSMase, which is able to hydrolyze some SM mole‐ cules, thus allowing nutrients, but not host antibodies, to access proteins at the hostparasite interface [96]. Excessive activation of the elusive nSMase using the unsaturated FA, ARA led to larval and adult worm surface membrane antigens exposure and eventu‐ al attrition [95-97]. The identification and sequence of *S. mansoni* putative nSMase was reported by Berriman et al. in 2009 [98; Accession number XP\_002578732.1]. The mole‐ cule of 70.99 kDa was shown to consist of 631 amino acids (aa) with an N-terminal, 300 aa Mg++-dependent exonuclease/endonuclease/ phosphatase (EEP) superfamily catalytic domain, and predicted 7 transmembrane regions at aa locations 355-377, 392-414, 435-457, 461-483, 527-549, 564-586 and 595-617 (genedb. org/ gene/ Smp\_162880). The *S*. *mansoni* putative nSMase showed about 52% homology with the amino terminal 300 aa of *Mus musculus* and human nSMase 1, which consists of 419 and 423 aa, respectively, an exonuclease/endonuclease/phosphatase superfamily domain at the N-terminus, and two transmembrane domains at the C-terminus.

Using primers based on the published sequence of *S. mansoni* nSMase, El Halbousy, Tallima, and El Ridi (personal communication) succeeded in cloning and sequencing 836 bp near the 5' end of *S*. *haematobium* nSMase-encoding mRNA. The predicted aa sequences correspond‐ ed to aa18- aa277 in the *S. mansoni* counterpart with 96% identities and 98% positives (Figure 2), and contained the conserved domains characterizing the EEP superfamily.

cive to nSMase inactivation (pH less than 7.2, high concentrations of nitric oxide or hy‐ drogen peroxide), do not allow neither antibodies nor even very small molecules (less than 600 Da) to access their surface membrane molecules [96]. Sphingomyelin appears critical in maintaining the rigidity and impermeability of the parasite outer lipid bilayer, likely via the ability of hydroxyl and amide groups in the interfacial region of sphingoli‐ pids to form with water molecules a tight netwok of hydrogen bonds [96, and references therein]. Recently, quasi-elastic and inelastic neutron scattering experiments on *S. manso‐ ni* and *S. haematobium* worms and larvae have been performed. The obtained experimen‐ tal findings suggest that the larva-medium interaction is triggered by the hydrogen bond network. Furthermore, the strength of that hydrogen bond network-based interaction ap‐ peared to be higher for *S. mansoni* larvae than adult worms and for *S. mansoni* than *S. haematobium* [Federica Migliardo, Unpublished Observations]. 3- Inhibition of ex vivo lar‐ vae SM synthesis or moderate nSMase activation (exposure to low concentrations of un‐ saturated FA, especially ARA) allows specific antibody access and visualization of surface membrane antigens. Exposure of ex vivo larvae to conditions conducive to exces‐ sive nSMase activation (hypoxia, high concentrations of unsaturated FA, notably ARA)

**3.4. Evidence for the existence of parasite tegument-associated nSMase and its activation**

In 2006, we predicted, and provided evidence for, the existence of a schistosome tegu‐ ment-associated Mg2+-dependent nSMase, which is able to hydrolyze some SM mole‐ cules, thus allowing nutrients, but not host antibodies, to access proteins at the hostparasite interface [96]. Excessive activation of the elusive nSMase using the unsaturated FA, ARA led to larval and adult worm surface membrane antigens exposure and eventu‐ al attrition [95-97]. The identification and sequence of *S. mansoni* putative nSMase was reported by Berriman et al. in 2009 [98; Accession number XP\_002578732.1]. The mole‐ cule of 70.99 kDa was shown to consist of 631 amino acids (aa) with an N-terminal, 300 aa Mg++-dependent exonuclease/endonuclease/ phosphatase (EEP) superfamily catalytic domain, and predicted 7 transmembrane regions at aa locations 355-377, 392-414, 435-457, 461-483, 527-549, 564-586 and 595-617 (genedb. org/ gene/ Smp\_162880). The *S*. *mansoni* putative nSMase showed about 52% homology with the amino terminal 300 aa of *Mus musculus* and human nSMase 1, which consists of 419 and 423 aa, respectively, an exonuclease/endonuclease/phosphatase superfamily domain at the N-terminus, and

Using primers based on the published sequence of *S. mansoni* nSMase, El Halbousy, Tallima, and El Ridi (personal communication) succeeded in cloning and sequencing 836 bp near the 5' end of *S*. *haematobium* nSMase-encoding mRNA. The predicted aa sequences correspond‐ ed to aa18- aa277 in the *S. mansoni* counterpart with 96% identities and 98% positives (Figure

2), and contained the conserved domains characterizing the EEP superfamily.

lead to their irreversible attrition [96, and references therein].

two transmembrane domains at the C-terminus.

**by arachidonic acid**

186 Parasitic Diseases - Schistosomiasis

**Figure 2.** Homology between predicted amino acid sequences of *S. mansoni* (SMnSM) and *S*. *haematobium* (SHnSM) neutral sphingomyelinase.

A systematically improved high quality genome and transcriptome of the human blood fluke *S. mansoni* was recently reported by Protasio et al. (unpublished observations), where‐ by sequence for *S. mansoni* putative nSMase was now shown to encode 431 (CCD60196.1) and not 631 (XP\_002578732.1) aa and 100% identity with the latter sequence only for the first 345 aa, as only 2 transmembrane domains were identified near the carboxyl end, between aa 325 and 375.

It is of note that the whole-genome sequence of *S*. *haematobium* was recently published [99], and reported the coding sequence (1038 bp) of an *S. haematobium* putative neutral sphingo‐ myelinase (http://www.schistodb.net; Sha\_103241), encoding 345 aa, with 3 transmembrane domains at the carboxyl end. Blasting of our SHnSM sequences with Sha\_103241 revealed 94-97% homology. However, the sretch of SHnSm aa33-116 (highlighted in Figure 2), which contained EEP superfamily signature sites and showed complete homology with the *S. man‐ soni* counterpart, was lacking in Sha\_103241 published sequence.

Antibodies specific to *S. mansoni* nSMase were generated in mice, immunized with peptides based on the molecule predicted aa sequence, synthesized as multiple antigen peptide (MAP) constructs. We were able to confirm the presence of the enzyme in adult male and female *S. mansoni* and *S*. *haematobium* tegument as judged by enzyme-linked immunosorb‐ ent assay (ELISA) and membrane and cytoplasmic IF. We were also the first to measure nSMase enzymatic activity in Triton X-100-solubilized surface membrane (Sup 1) and whole worm soluble (SWAP) molecules of male and female *S. mansoni* and *S. haematobium*. Neutral, but no acidic, sphingomyelinase activity was readily detectable by the Amplex Red Sphin‐ gomyelinase Assay, and increased with incubation time and protein amount. The nSMase activity of Sup 1 and SWAP of male and female *S*. *mansoni* and *S. haematobium* adult worms was significantly (*P* < 0.05 - < 0.0001) increased following exposure to 125 or 250 mM linoleic acid, ARA, docosahexaenoic acid, or phosphatidyl serine, with ARA consistently showing the highest nSMase activating potential [100].

have achieved invisibility", and if it were not for the parasite "scent", the excretory-secreto‐

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

189

Excretory-secretory products of cercariae, in vitro cultured and ex vivo lung-stage schis‐ tosomula, and adult worms of *S. mansoni, S. japonicum* [8,17,105-111], and *S. haematobium* as well [99] have been identified in several studies, and were found to be dominated by actin, enolase, aldolase, GST,TPI, glyceraldehyde-3 phosphate dehydrogenase (SG3PDH), thioredoxin peroxidease (TPX) = peroxyredoxin, proteases, and calcium-binding proteins,

Cercarial ESP would activate innate immune cells in the epidermis and dermis [8-11,111-117], but would not be targeted by antibody or complement products in the bloodand lymph-free epidermis. In the dermis, larval ESP may interact with host innate effectors, such as natural antibodies, serum lectins and complement components, resulting into in‐ flammation that would facilitate the parasite entry into dermal blood capillaries. Schistoso‐ mula then migrate via the venous system in relatively large vessels, whereby ESP are quickly "washed" away by neutrophils and monocytes. In contrast, lung-stage larvae ESP likely stagnate in the narrow, convoluted, and notably thin-walled lung capillaries and liver sinusoids. These sites are the most strenuous of the journey, an occasion for the parasite to get rid of the less fit "members", and an explanation for the lung-stage and pre-adult larvae being documented as the target of innate and acquired resistance to schistosomiasis [1,118]. Adult worms reside in vessels, which are neither narrow nor thin-walled, and accordingly, the large ESP amounts they release are rapidly pinocytosed or phagocytosed, and transport‐ ed away from the worms for stimulation of rather innocuous immune responses in the

**6. The plausible mechanism of innate and immune attrition of invading**

Migrating larvae ESP presented by blood monocytes and dendritic cells trigger Th lympho‐ cytes in host spleen for production of predominantly Th1 (IFN-g and TNF) and Th17 (IL-17) cytokines [14,15,17-19], especially if the host was previously RA-vaccinated [16,118] or im‐ munized with vaccine candidate antigens in conjunction with Th1 adjuvants [62-68]. Addi‐ tionally, larval ESP- antibody complexes may activate immune effector cells via FcR binding. Stimulated monocytes produce nitric oxide and reactive oxygen products [119], which are lethal to near-by schistosomules; however, these toxic molecules inhibit the para‐ site tegument-associated nSMase activity, leading to outer membrane entire impermeability [95,96,120,121]. Neutrophils recruited and activated by Th17 cytokines likely ensnare larvae in their extracellular traps, yet secrete proteases and other enzymes that might all be ineffec‐ tive because of the worm tight lipid bilayer and inaccessibility of surface membrane mole‐

Eosinophils also produce extracellular traps, and their basic molecules would be severely toxic to captured schistomula [124,125]. Basophils release cytotoxic basic molecules, and

ry products (ESP), a schistosomiasis vaccine would be as good as over.

spleen, the principal target for intravascular antigens.

namely calpain.

**larvae**

cules [119,122,123].

## **4. Arachidonic acid as a remedy for schistosomiasis**

Since incubation of *S. mansoni* and *S. haematobium* ex vivo larvae [95,96] and adult worms [97] with ARA leads to exposure of surface membrane antigens and eventual attrition, it was rational to propose ARA for chemotherapy of schistosomiasis. ARA could be schistosomici‐ dal per se, and additionally would expose the parasite surface membrane molecules to host antibodies-mediated attack, thus eliciting drug and immune system synergy.

In our studies, pure ARA from Sigma was used for in vitro and preliminary in vivo studies, while ARA from Martek was used for in vivo studies [101,102]. We have dem‐ onstrated that 5 mM pure ARA (Sigma) leads to irreversible killing of ex vivo larval, ju‐ venile, pre-adult and adult *S. manson*i and *S. haematobium* worms, within 1- 5 hr, depending on the parasite age, and the fetal calf serum concentration. ARA-mediated worm attrition was prevented by nSMase inhibitors such as CaCl2 and GW4869. Electron microscopy studies revealed entire disruption of the outer lipid bilayers, the strength of which correlated with ARA concentration. These consistent and reproducible findings in‐ dicate that ARA is schistosomicidal per se [101].

ARA-mediated *S. mansoni* and *S*. *haematobium* worm in vitro attrition was reproduced in vivo whereby a series of 20 independent experiments, using BALB/c or C57BL/6 mice or Sy‐ rian hamsters, indicated that oral administration of 300-2500 mg/kg ARA in a pure form (Sigma), included in infant formula (Nestle), or capsules (X Factor, Molecular Nutrition), on 2 consecutive days, consistently led to between 50 and 80% decrease in *S. mansoni* or *S. hae‐ matobium* worm burden [101,102]. ARA-mediated attrition in vivo appeared to be associated with high titers of serum antibodies to tegumental antigens, because it was significantly higher when treatment was started at 8, rather than 5 or 6, week post infection with *S. man‐ soni*. Immune responses to adult worm tegumental antigens are certainly powerful in adults and children with patent or chronic schistosomiasis, and ARA is already marketed for hu‐ man use in USA and Canada for proper development of newborns, and muscle growth of athletes. Accordingly, it is recommended to start pre-clinical and clinical studies in human volunteers for development of ARA as a safe and cost-effective remedy to schistosomiasis, especially that no ARA-related adverse effects were seen in any experiment in mice or ham‐ sters [101-103].

## **5. Larval excretory-secretory products as vaccine candidates**

Schistosome cytosolic and surface membrane antigens are entirely hidden, inaccessible to the host immune system effectors. As spelled out by Patrick Skelly [104], "schistosomes have achieved invisibility", and if it were not for the parasite "scent", the excretory-secreto‐ ry products (ESP), a schistosomiasis vaccine would be as good as over.

activity of Sup 1 and SWAP of male and female *S*. *mansoni* and *S. haematobium* adult worms was significantly (*P* < 0.05 - < 0.0001) increased following exposure to 125 or 250 mM linoleic acid, ARA, docosahexaenoic acid, or phosphatidyl serine, with ARA consistently showing

Since incubation of *S. mansoni* and *S. haematobium* ex vivo larvae [95,96] and adult worms [97] with ARA leads to exposure of surface membrane antigens and eventual attrition, it was rational to propose ARA for chemotherapy of schistosomiasis. ARA could be schistosomici‐ dal per se, and additionally would expose the parasite surface membrane molecules to host

In our studies, pure ARA from Sigma was used for in vitro and preliminary in vivo studies, while ARA from Martek was used for in vivo studies [101,102]. We have dem‐ onstrated that 5 mM pure ARA (Sigma) leads to irreversible killing of ex vivo larval, ju‐ venile, pre-adult and adult *S. manson*i and *S. haematobium* worms, within 1- 5 hr, depending on the parasite age, and the fetal calf serum concentration. ARA-mediated worm attrition was prevented by nSMase inhibitors such as CaCl2 and GW4869. Electron microscopy studies revealed entire disruption of the outer lipid bilayers, the strength of which correlated with ARA concentration. These consistent and reproducible findings in‐

ARA-mediated *S. mansoni* and *S*. *haematobium* worm in vitro attrition was reproduced in vivo whereby a series of 20 independent experiments, using BALB/c or C57BL/6 mice or Sy‐ rian hamsters, indicated that oral administration of 300-2500 mg/kg ARA in a pure form (Sigma), included in infant formula (Nestle), or capsules (X Factor, Molecular Nutrition), on 2 consecutive days, consistently led to between 50 and 80% decrease in *S. mansoni* or *S. hae‐ matobium* worm burden [101,102]. ARA-mediated attrition in vivo appeared to be associated with high titers of serum antibodies to tegumental antigens, because it was significantly higher when treatment was started at 8, rather than 5 or 6, week post infection with *S. man‐ soni*. Immune responses to adult worm tegumental antigens are certainly powerful in adults and children with patent or chronic schistosomiasis, and ARA is already marketed for hu‐ man use in USA and Canada for proper development of newborns, and muscle growth of athletes. Accordingly, it is recommended to start pre-clinical and clinical studies in human volunteers for development of ARA as a safe and cost-effective remedy to schistosomiasis, especially that no ARA-related adverse effects were seen in any experiment in mice or ham‐

the highest nSMase activating potential [100].

188 Parasitic Diseases - Schistosomiasis

dicate that ARA is schistosomicidal per se [101].

sters [101-103].

**4. Arachidonic acid as a remedy for schistosomiasis**

antibodies-mediated attack, thus eliciting drug and immune system synergy.

**5. Larval excretory-secretory products as vaccine candidates**

Schistosome cytosolic and surface membrane antigens are entirely hidden, inaccessible to the host immune system effectors. As spelled out by Patrick Skelly [104], "schistosomes Excretory-secretory products of cercariae, in vitro cultured and ex vivo lung-stage schis‐ tosomula, and adult worms of *S. mansoni, S. japonicum* [8,17,105-111], and *S. haematobium* as well [99] have been identified in several studies, and were found to be dominated by actin, enolase, aldolase, GST,TPI, glyceraldehyde-3 phosphate dehydrogenase (SG3PDH), thioredoxin peroxidease (TPX) = peroxyredoxin, proteases, and calcium-binding proteins, namely calpain.

Cercarial ESP would activate innate immune cells in the epidermis and dermis [8-11,111-117], but would not be targeted by antibody or complement products in the bloodand lymph-free epidermis. In the dermis, larval ESP may interact with host innate effectors, such as natural antibodies, serum lectins and complement components, resulting into in‐ flammation that would facilitate the parasite entry into dermal blood capillaries. Schistoso‐ mula then migrate via the venous system in relatively large vessels, whereby ESP are quickly "washed" away by neutrophils and monocytes. In contrast, lung-stage larvae ESP likely stagnate in the narrow, convoluted, and notably thin-walled lung capillaries and liver sinusoids. These sites are the most strenuous of the journey, an occasion for the parasite to get rid of the less fit "members", and an explanation for the lung-stage and pre-adult larvae being documented as the target of innate and acquired resistance to schistosomiasis [1,118]. Adult worms reside in vessels, which are neither narrow nor thin-walled, and accordingly, the large ESP amounts they release are rapidly pinocytosed or phagocytosed, and transport‐ ed away from the worms for stimulation of rather innocuous immune responses in the spleen, the principal target for intravascular antigens.

## **6. The plausible mechanism of innate and immune attrition of invading larvae**

Migrating larvae ESP presented by blood monocytes and dendritic cells trigger Th lympho‐ cytes in host spleen for production of predominantly Th1 (IFN-g and TNF) and Th17 (IL-17) cytokines [14,15,17-19], especially if the host was previously RA-vaccinated [16,118] or im‐ munized with vaccine candidate antigens in conjunction with Th1 adjuvants [62-68]. Addi‐ tionally, larval ESP- antibody complexes may activate immune effector cells via FcR binding. Stimulated monocytes produce nitric oxide and reactive oxygen products [119], which are lethal to near-by schistosomules; however, these toxic molecules inhibit the para‐ site tegument-associated nSMase activity, leading to outer membrane entire impermeability [95,96,120,121]. Neutrophils recruited and activated by Th17 cytokines likely ensnare larvae in their extracellular traps, yet secrete proteases and other enzymes that might all be ineffec‐ tive because of the worm tight lipid bilayer and inaccessibility of surface membrane mole‐ cules [119,122,123].

Eosinophils also produce extracellular traps, and their basic molecules would be severely toxic to captured schistomula [124,125]. Basophils release cytotoxic basic molecules, and most importantly, pharmacologic mediators able to modulate endothelial integrity, thus en‐ couraging larvae to escape extravascularly to a certain demise [126]. Indeed, that attrition mechanism was shown to be of great importance in resistance to challenge infection in the RA model [118]. However, eosinophils and basophils are recruited and activated by type 2 cytokines [125,126], and thus, are prevented from active participation in the hunt for devel‐ oping larvae [1,19] following infection of naive and antigens/Th1 adjuvant-immunized mice. Nevertheless, attempts to vaccinate mice against schistosomiasis uniformly aim at enhanc‐ ing Th1 immune responses, in spite of the documented role of Th2 cytokines, namely IL-4, in protection of RA immunized mice [127-130]. Also in rats, sterile resistance to *S. mansoni* is associated with production of IL-4, IL-5, and IL-13, while susceptibility is accompanied with elevated expression of IFN-g [131,132 ]. In humans, a good association was previously ob‐ served between serum IgE production and resistance to infection after chemotherapy [41-43]. Indeed, Fallon et al. [133] reported that "adult resistance and child susceptibly to re‐ infection after chemotherapy have been described for all 3 *Schistosoma* species that most commonly infect man. For all 3 parasite species, the immunological correlates of this agedependent resistance are associated with type 2 responses". These findings were entirely confirmed in recent studies [134-136].

immunized individuals, will likely lead to full control, and eventual elimination of schisto‐

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

191

Experiments. related to novel approaches to therapy and vaccination were supported, in part, by the Science and Technology Development Fund, Egypt, grants No. 144 and 2073 to

R. El Ridi. We are indebted to Mr. Abdel Badih Foda for help and assistance.

\*Address all correspondence to: rashikaelridi@hotmail.com, rashika@mailer.eun.eg

[1] von Lichtenberg F, Sher A, McIntyre S. A lung model of schistosome immunity in

[2] King CH. Parasites and poverty: the case of schistosomiasis. Acta Tropica

[3] Hotez P. Enlarging the "Audacious Goal": elimination of the world's high prevalence

[4] Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infectious Diseases

[5] He YX, Chen L, Ramaswamy K. Schistosoma mansoni, S. haematobium, and S. japo‐ nicum: early events associated with penetration and migration of schistosomula

[6] Curwen RS, Wilson RA. Invasion of skin by schistosome cercariae: some neglected

[7] Stirewalt MA. Schistosoma mansoni: cercaria to schistosomule. Advances in Parasi‐

[8] Harrop R, Jennings N, Mountford AP, Coulson PS, Wilson RA. Characterization, cloning and immunogenicity of antigens released by transforming cercariae of Schis‐

through human skin. Experimental Parasitolology 2002;102(2): 99-108.

facts. Trends in Parasitolology 2003;19(2): 63-66.

tosoma mansoni. Parasitology 2000;121 ( Pt 4): 385-394.

Zoology Department, Faculty of Science, Cairo University, Cairo, Egypt

mice. American Journal of Pathology 1977;87(1): 105-123.

neglected tropical diseases. Vaccine 2011;29 Suppl 4:D104-110.

somiasis.

**Author details**

**References**

Rashika El Ridi and Hatem Tallima

2010;113(2): 95-104.

2010;10(10):733-736.

tology 1974;12: 115-182.

## **7. The road to a sterilizing schistosomiasis vaccine**

Larval ESP are innumerable, among which we have selected those eliciting the weakest Th1 and Th17 responses, namely SG3PDH in a recombinant (rSG3PDH) form and a TPX MAP construct [19,110]. Nevetheless, it was critical to use an adjuvant that would skew the larval immune responses towards the Th2 axis. In contrast to incomplete Freund's adjuvant, alum, polyinosinic-polycytidylic acid, and peptidoglycan, the Th2 master cytokine, thymic stromal lymphopoietin (TSLP), succeeded in directing the ESP-mediated immune responses towards a Th2-biased profile in prototypical Th1 (C57BL/6) and Th2 (BALB/c) mice [110,137]. There‐ after, we have immunized outbred, akin to humans, mice with rSG3PDH and TPX MAP in conjunction with the type 2 cytokines, TSLP, IL-25, or IL-33 [138, and references therein]. Re‐ sults of 8 independent experiments indicated that these formulations elicited IgM, IgG1, and IgA specific antibodies, and an increase in ex vivo spleen cells release of IL-4, IL-5, and IL-13 correlated with consistent, reproducible, and highly significant (*P* < 0.0001) reduction of 62% to 78% in challenge *S. mansoni* worm burden [138]. Similar studies using *S. haematobium* are now in progress.

#### **8. Conclusion**

Improved selection of larval ESP, singly or in a mixture, and type 2 adjuvant is expected to result into a sterilizing vaccine against schistosome infection. Concurrent development of ARA, a nutrient, a component of our cell membranes, for chemotherapy of infection in un‐ immunized individuals, will likely lead to full control, and eventual elimination of schisto‐ somiasis.

Experiments. related to novel approaches to therapy and vaccination were supported, in part, by the Science and Technology Development Fund, Egypt, grants No. 144 and 2073 to R. El Ridi. We are indebted to Mr. Abdel Badih Foda for help and assistance.

## **Author details**

most importantly, pharmacologic mediators able to modulate endothelial integrity, thus en‐ couraging larvae to escape extravascularly to a certain demise [126]. Indeed, that attrition mechanism was shown to be of great importance in resistance to challenge infection in the RA model [118]. However, eosinophils and basophils are recruited and activated by type 2 cytokines [125,126], and thus, are prevented from active participation in the hunt for devel‐ oping larvae [1,19] following infection of naive and antigens/Th1 adjuvant-immunized mice. Nevertheless, attempts to vaccinate mice against schistosomiasis uniformly aim at enhanc‐ ing Th1 immune responses, in spite of the documented role of Th2 cytokines, namely IL-4, in protection of RA immunized mice [127-130]. Also in rats, sterile resistance to *S. mansoni* is associated with production of IL-4, IL-5, and IL-13, while susceptibility is accompanied with elevated expression of IFN-g [131,132 ]. In humans, a good association was previously ob‐ served between serum IgE production and resistance to infection after chemotherapy [41-43]. Indeed, Fallon et al. [133] reported that "adult resistance and child susceptibly to re‐ infection after chemotherapy have been described for all 3 *Schistosoma* species that most commonly infect man. For all 3 parasite species, the immunological correlates of this agedependent resistance are associated with type 2 responses". These findings were entirely

Larval ESP are innumerable, among which we have selected those eliciting the weakest Th1 and Th17 responses, namely SG3PDH in a recombinant (rSG3PDH) form and a TPX MAP construct [19,110]. Nevetheless, it was critical to use an adjuvant that would skew the larval immune responses towards the Th2 axis. In contrast to incomplete Freund's adjuvant, alum, polyinosinic-polycytidylic acid, and peptidoglycan, the Th2 master cytokine, thymic stromal lymphopoietin (TSLP), succeeded in directing the ESP-mediated immune responses towards a Th2-biased profile in prototypical Th1 (C57BL/6) and Th2 (BALB/c) mice [110,137]. There‐ after, we have immunized outbred, akin to humans, mice with rSG3PDH and TPX MAP in conjunction with the type 2 cytokines, TSLP, IL-25, or IL-33 [138, and references therein]. Re‐ sults of 8 independent experiments indicated that these formulations elicited IgM, IgG1, and IgA specific antibodies, and an increase in ex vivo spleen cells release of IL-4, IL-5, and IL-13 correlated with consistent, reproducible, and highly significant (*P* < 0.0001) reduction of 62% to 78% in challenge *S. mansoni* worm burden [138]. Similar studies using *S. haematobium* are

Improved selection of larval ESP, singly or in a mixture, and type 2 adjuvant is expected to result into a sterilizing vaccine against schistosome infection. Concurrent development of ARA, a nutrient, a component of our cell membranes, for chemotherapy of infection in un‐

confirmed in recent studies [134-136].

190 Parasitic Diseases - Schistosomiasis

now in progress.

**8. Conclusion**

**7. The road to a sterilizing schistosomiasis vaccine**

Rashika El Ridi and Hatem Tallima

\*Address all correspondence to: rashikaelridi@hotmail.com, rashika@mailer.eun.eg

Zoology Department, Faculty of Science, Cairo University, Cairo, Egypt

## **References**


[9] Pivarcsi A, Kemény L, Dobozy A. Innate immune functions of the keratinocytes. A review. Acta Microbiologica Immunologica Hungarica 2004;51(3): 303-310.

[22] Abruzzi A, Fried B. Coinfection of Schistosoma (Trematoda) with bacteria, protozoa

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

193

[23] Farid A, Al-Sherbiny M, Osman A, Mohamed N, Saad A, Shata MT, Lee DH, Prince AM, Strickland GT. Schistosoma infection inhibits cellular immune responses to core

[24] Secor WE. The effects of schistosomiasis on HIV/AIDS infection, progression and

[25] Botelho MC, Machado JC, da Costa JM. Schistosoma haematobium and bladder can‐

[26] El Ridi R, El Garem AA. Is an anti-Schistosoma haematobium vaccine necessary? In‐

[27] Davie J. Medical Ecology-Schistosomiasis. In Parasitic Diseases 5th Edition. Chapter

[28] Mehlhorn H, Becker B, Andrews P, Thomas H, Frenkel JK. In vivo and in vitro ex‐ periments on the effects of praziquantel on Schistosoma mansoni. A light and elec‐

[29] Linder E, Thors C. Schistosoma mansoni: praziquantel-induced tegumental lesion ex‐ poses actin of surface spines and allows binding of actin depolymerizing factor, gel‐

[30] Tallima H, El Ridi R. Praziquantel binds Schistosoma mansoni adult worm actin. In‐

[31] Tallima H, El Ridi R. Re: is actin the praziquantel receptor? International Journal of

[32] Pica-Mattoccia L, Valle C, Basso A, Troiani AR, Vigorosi F, Liberti P, Festucci A, Cioli D. Cytochalasin D abolishes the schistosomicidal activity of praziquantel. Experi‐

[33] Pica-Mattoccia L, Orsini T, Basso A, Festucci A, Liberti P, Guidi A, Marcatto-Maggi AL, Nobre-Santana S, Troiani AR, Cioli D, Valle C. Schistosoma mansoni: lack of cor‐ relation between praziquantel-induced intra-worm calcium influx and parasite

[34] Gnanasekar M, Salunkhe AM, Mallia AK, He YX, Kalyanasundaram R. Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni. Antimicrobial

[35] Viola A, Gupta N. Tether and trap: regulation of membrane-raft dynamics by actin-

[36] Allen HE, Crompton DW, de Silva N, LoVerde PT, Olds GR. New policies for using anthelmintics in high risk groups. Trends in Parasitology 2002;18(9): 381-382.

binding proteins. Nature Reviews Immunology 2007;7(11): 889-896.

and helminths. Advances in Parasitology 2011;77: 1-85.

HCV peptides. Parasite Immunology 2005;27(5): 189-196.

cer: what lies beneath? Virulence 2010;1(2): 84-87.

35. www.medicalecology.org/water/w\_schist.htm

solin. Parasitology 1992; 105(Pt 1): 71-79.

Antimicrobial Agents 2007;30(6): 566-567.

mental Parasitology 2007;115(4): 344-351.

death. Experimental Parasitology 2008;119(3): 332-335.

Agents and Chemotherapy 2009;53(3): 1054-1060.

ternational Journal for Parasitology 1999;29(4): 651-653.

transmission. Current Opinion in HIV and AIDS 2012;7(3): 254-259.

tron microscopic study. Arzneimittelforschung 1981;31(3a): 544-554.

ternational Journal of Antimicrobial Agents 2007;29(5): 570-575.


[22] Abruzzi A, Fried B. Coinfection of Schistosoma (Trematoda) with bacteria, protozoa and helminths. Advances in Parasitology 2011;77: 1-85.

[9] Pivarcsi A, Kemény L, Dobozy A. Innate immune functions of the keratinocytes. A review. Acta Microbiologica Immunologica Hungarica 2004;51(3): 303-310.

[10] Chen L, Rao KV, He YX, Ramaswamy K. Skin-stage schistosomula of Schistosoma mansoni produce an apoptosis-inducing factor that can cause apoptosis of T cells.

[11] Paveley RA, Aynsley SA, Cook PC, Turner JD, Mountford AP. Fluorescent imaging of antigen released by a skin-invading helminth reveals differential uptake and acti‐ vation profiles by antigen presenting cells. PLoS Neglected Tropical Diseases

[12] Schistosoma, blood fluke. http://www.metapathogen.com/schistosoma/ (accessed 22

[13] Rheinberg CE, Moné H, Caffrey CR, Imbert-Establet D, Jourdane J, Ruppel A. Schis‐ tosoma haematobium, S. intercalatum, S. japonicum, S. mansoni, and S. rodhaini in mice: relationship between patterns of lung migration by schistosomula and perfu‐

[14] Grzych JM, Pearce E, Cheever A, Caulada ZA, Caspar P, Heiny S, Lewis F, Sher A. Egg deposition is the major stimulus for the production of Th2 cytokines in murine

[15] Pearce EJ, Caspar P, Grzych JM, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schisto‐

[16] Mountford AP, Harrop R, Wilson RA. Antigens derived from lung-stage larvae of Schistosoma mansoni are efficient stimulators of proliferation and gamma interferon secretion by lymphocytes from mice vaccinated with attenuated larvae. Infection and

[17] Harrop R, Coulson PS, Wilson RA. Characterization, cloning and immunogenicity of antigens released by lung-stage larvae of Schistosoma mansoni. Parasitology1999;118

[18] Tallima H, Salah M, Guirguis FR, El Ridi R. Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni. Cytokine

[19] El Ridi R, Tallima H, Mahana N, Dalton JP. Innate immunogenicity and in vitro pro‐ tective potential of Schistosoma mansoni lung schistosomula excretory-secretory can‐

[20] Walker AJ. Insights into the functional biology of schistosomes. Parasites and Vectors

[21] Andersson KL, Chung RT. Hepatic schistosomiasis. Current Treatment Options in

didate vaccine antigens. Microbes and Infection 2010;12(10): 700-709.

sion recovery of adult worms. Parasitology Research 1998;84(4): 338-342.

schistosomiasis mansoni. Journal of Immunology 1991;146(4): 1322-1327.

soma mansoni. Journal of Experimental Medicine 1991;173(1): 159-166.

Journal of Biological Chemistry 2002;277(37): 34329-34335.

2009;3(10): e528.

Immunity 1995;63(5): 1980-1986.

Gastroenterology 2007;10: 504-512.

( Pt 6): 583-594.

2009;48(3): 239-245.

2011;4: 203.

April 2012).

192 Parasitic Diseases - Schistosomiasis


[37] Landouré A, Dembélé R, Goita S, Kané M, Tuinsma M, Sacko M, Toubali E, French MD, Keita AD, Fenwick A, Traoré MS, Zhang Y. Significantly reduced intensity of in‐ fection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment. PLoS Neglected Tropical Diseases 2012;6(7): e1774.

[49] Moser D, Tendler M, Griffiths G, Klinkert MQ. A 14-kDa Schistosoma mansoni poly‐ peptide is homologous to a gene family of fatty acid binding proteins. Journal of Bio‐

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

195

[50] Reynolds SR, Shoemaker CB, Harn DA. T and B cell epitope mapping of Sm23, an integral membrane protein of Schistosoma mansoni. Journal of Immunology

[51] Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, Dekaban GA, Clarke MW. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochimica et Biophysica Acta

[52] El Ridi R, Abdel Tawab N, Guirguis N. Schistosoma mansoni: identification and pro‐ tective immunity of adult worm antigens recognized by T lymphocytes of outbred Swiss mice immunized with irradiated cercariae. Experimental Parasitology

[53] Abdel Tawab N. Identification and molecular characterization of protective antigens against murine schistosomiasis mansoni. PhD thesis. Faculty of Science, Cairo Uni‐

[54] Osman A, El Ridi R, Guirguis N, Dean DA. Identification of Schistosoma mansoni antigens recognized by T cells of C57BL/6 mice immunized with gamma-irradiated

[55] Osman A, El Ridi R, Guirguis N, Dean DA. Identification of Schistosoma mansoni antigens recognized by spleen cells of C57B1/6 mice immunized with ultraviolet-irra‐

[56] El Gengehi N, El Ridi R, Tawab NA, El Demellawy M, Mangold BL. A Schistosoma mansoni 62-kDa band is identified as an irradiated vaccine T-cell antigen and charac‐

[57] Dessein AJ, Begley M, Demeure C, Caillol D, Fueri J, dos Reis MG, Andrade ZA, Pra‐ ta A, Bina JC. Human resistance to Schistosoma mansoni is associated with IgG reac‐ tivity to a 37-kDa larval surface antigen. Journal of Immunology 1988;140(8):

[58] Goudot-Crozel V, Caillol D, Djabali M, Dessein AJ. The major parasite surface anti‐ gen associated with human resistance to schistosomiasis is a 37-kD glyceralde‐ hyde-3P-dehydrogenase. Journal of Experimental Medicine 1989;170(6): 2065-2080.

[59] Charrier-Ferrara S, Caillol D, Goudot-Crozel V. Complete sequence of the Schistoso‐ ma mansoni glyceraldehyde-3-phosphate dehydrogenase gene encoding a major sur‐

[60] El Ridi R, Farouk F, Sherif M, Al-Sherbiny M, Osman A, El Gengehi N, Shoemaker CB. T and B cell reactivity to a 42-kDa protein is associated with human resistance to

face antigen. Molecular and Biochemical Parasitology 1992;56(2): 339-343.

diated cercariae. International Journal for Parasitology 194;24(7): 943-950.

terized as calreticulin. Journal of Parasitology 2000;86(5): 993-1000.

cercariae. Journal of Parasitology 1994;80 (3); 421-431.

logical Chemistry 1991;266(13):8447-8454.

1992;149(12) :3995-4001.

1993;1181(1): 37-44.

1993;76(3): 265-277.

versity;1994.

2727-2736.


[49] Moser D, Tendler M, Griffiths G, Klinkert MQ. A 14-kDa Schistosoma mansoni poly‐ peptide is homologous to a gene family of fatty acid binding proteins. Journal of Bio‐ logical Chemistry 1991;266(13):8447-8454.

[37] Landouré A, Dembélé R, Goita S, Kané M, Tuinsma M, Sacko M, Toubali E, French MD, Keita AD, Fenwick A, Traoré MS, Zhang Y. Significantly reduced intensity of in‐ fection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment. PLoS Neglected Tropical Diseases 2012;6(7): e1774. [38] Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mu‐ tuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES. Re‐ duced susceptibility to praziquantel among naturally occurring Kenyan isolates of

Schistosoma mansoni. PLoS Neglected Tropical Diseases 2009;3(8): e504.

ry strain of Schistosoma mansoni. Acta Tropica 2009;111(1): 82-85.

2009;136(12):1581-1592.

ogy1999;118 (Pt 1): 101-105.

ture 1987;326(6109): 149-153.

cal Medicine and Hygiene 1987;81(1): 29-35.

625-632.

194 Parasitic Diseases - Schistosomiasis

562-567.

593-596.

[39] Pica-Mattoccia L, Doenhoff MJ, Valle C, Basso A, Troiani AR, Liberti P, Festucci A, Guidi A, Cioli D. Genetic analysis of decreased praziquantel sensitivity in a laborato‐

[40] Wilson RA. The saga of schistosome migration and attrition. Parasitology

[41] Hagan P, Wilkins HA, Blumenthal UJ, Hayes RJ, Greenwood BM. Eosinophilia and resistance to Schistosoma haematobium in man. Parasite Immunology 1985;7(6):

[42] Wilkins HA, Blumenthal UJ, Hagan P, Hayes RJ, Tulloch S. Resistance to reinfection after treatment of urinary schistosomiasis. Transactions of the Royal Society of Tropi‐

[43] Kabatereine NB, Vennervald BJ, Ouma JH, Kemijumbi J, Butterworth AE, Dunne DW, Fulford AJ. Adult resistance to schistosomiasis mansoni: age-dependence of re‐ infection remains constant in communities with diverse exposure patterns. Parasitol‐

[44] Soisson LM, Masterson CP, Tom TD, McNally MT, Lowell GH, Strand M. Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistoso‐

[46] Harn DA, Wei G, Oligino LD, Mitsuyama M, Gebremichael A, Richter D. A protec‐ tive monoclonal antibody specifically recognizes and alters the catalytic activity of schistosome triose-phosphate isomerase. Journal of Immunology 1992;148(2):

[47] Shoemaker C, Gross A, Gebremichael A, Harn D. cDNA cloning and functional ex‐ pression of the Schistosoma mansoni protective antigen triose-phosphate isomerase.

Proceedings of the National Academy of Sciences USA 1992;89(5): 1842-1846. [48] Lanar DE, Pearce EJ, James SL, Sher A. Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice. Science 1986;234(4776):

ma mansoni surface antigen. Journal of Immunology 1992;149(11): 3612-3620. [45] Balloul JM, Sondermeyer P, Dreyer D, Capron M, Grzych JM, Pierce RJ, Carvallo D, Lecocq JP, Capron A. Molecular cloning of a protective antigen of schistosomes. Na‐


both schistosomiasis mansoni and haematobium. Journal of Infectious Diseases 1998;177(5): 1364-1372.

[71] Kassis AI, Aikawa M, Mahmoud AF. Mouse antibody-dependent eosinophil and macrophage adherence and damage to schistosomula of Schistosoma mansoni. Jour‐

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

197

[72] Balloul JM, Pierce RJ, Grzych JM, Capron A. In vitro synthesis of a 28 kilodalton anti‐ gen present on the surface of the schistosomulum of Schistosoma mansoni. Molecu‐

[73] ] Balloul JM, Grzych JM, Pierce RJ, Capron A. A purified 28,000 dalton protein from Schistosoma mansoni adult worms protects rats and mice against experimental schis‐

[74] Nutten S, Papin JP, Woerly G, Dunne DW, MacGregor J, Trottein F, Capron M. Selec‐ tin and Lewis(x) are required as co-receptors in antibody-dependent cell-mediated cytotoxicity of human eosinophils to Schistosoma mansoni schistosomula. European

[75] Moser G, Sher A. Studies of the antibody-dependent killing of schistosomula of Schistosoma mansoni employing haptenic target antigens. II. In vitro killing of TNPschistosomula by human eosinophils and neutrophils. Journal of Immunology

[76] Lehn M, Chiang CP, Remold HG, Swafford JR, Caulfield JP. Freshly isolated and cul‐ tured human monocytes obtained by plasmapheresis kill schistosomula of Schistoso‐

[77] Kusel JR, Gordon JF. Biophysical studies of the schistosome surface and their rele‐ vance to its properties under immune and drug attack. Parasite Immunology

[78] Gobert GN, Chai M, McManus DP. Biology of the schistosome lung-stage schisto‐

[79] Crabtree JE, Wilson RA. Schistosoma mansoni: a scanning electron microscope study

[80] Krautz-Peterson G, Camargo S, Huggel K, Verrey F, Shoemaker CB, Skelly PJ. Amino acid transport in schistosomes: Characterization of the permease heavy chain

[81] Krautz-Peterson G, Simoes M, Faghiri Z, Ndegwa D, Oliveira G, Shoemaker CB, Skelly PJ. Suppressing glucose transporter gene expression in schistosomes impairs parasite feeding and decreases survival in the mammalian host. PLoS Pathogens

[82] Da'dara A, Krautz-Peterson G, Faghiri Z, Skelly PJ. Metabolite movement across the

of the developing schistosomulum. Parasitology 1980;81(Pt 3): 553-564.

SPRM1hc. Journal of Biological Chemistry 2007;282(30): 21767-21775.

schistosome surface. Journal of Helminthology 2012;86(2): 141-147.

ma mansoni. American Journal of Pathology 1991;139(2): 399-411.

nal of Immunology 1979; 122(2): 398-405.

Journal of Immunology 1999;29(3): 799-808.

somulum. Parasitology 2007;134(Pt 4): 453-460.

1981;126(3): 1025-1029.

1989;11(5): 431-451.

2010;6(6): e1000932.

lar and Biochemical Parasitology 1985;17(1): 105-114.

tosomiasis. Journal of Immunology 1987;138(10): 3448-3453.


[71] Kassis AI, Aikawa M, Mahmoud AF. Mouse antibody-dependent eosinophil and macrophage adherence and damage to schistosomula of Schistosoma mansoni. Jour‐ nal of Immunology 1979; 122(2): 398-405.

both schistosomiasis mansoni and haematobium. Journal of Infectious Diseases

[61] El Ridi R, Shoemaker CB, Farouk F, El Sherif NH, Afifi A. Human T- and B-cell re‐ sponses to Schistosoma mansoni recombinant glyceraldehyde 3-phosphate dehydro‐ genase correlate with resistance to reinfection with S. mansoni or Schistosoma haematobium after chemotherapy. Infection and Immunity 2001;69(1): 237-244. [62] Da'dara AA, Skelly PJ, Wang MM, Harn DA. Immunization with plasmid DNA en‐ coding the integral membrane protein, Sm23, elicits a protective immune response

[63] Da'dara AA, Skelly PJ, Fatakdawala M, Visovatti S, Eriksson E, Harn DA. Compara‐ tive efficacy of the Schistosoma mansoni nucleic acid vaccine, Sm23, following micro‐

[64] Da'Dara AA, Skelly PJ, Walker CM, Harn DA. A DNA-prime/protein-boost vaccina‐ tion regimen enhances Th2 immune responses but not protection following Schisto‐

[65] Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, Don TA, McMa‐ nus DP, Correa-Oliveira R, Loukas A. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nature Medicine 2006;12(7):

[66] Zhang W, Li J, Duke M, Jones MK, Kuang L, Zhang J, Blair D, Li Y, McManus DP. Inconsistent protective efficacy and marked polymorphism limits the value of Schis‐ tosoma japonicum tetraspanin-2 as a vaccine target. PLoS Neglegted Tropical Diseas‐

[67] Pearson MS, Pickering DA, McSorley HJ, Bethony JM, Tribolet L, Dougall AM, Hotez PJ, Loukas A. Enhanced protective efficacy of a chimeric form of the schistosomiasis

vaccine antigen Sm-TSP-2. PLoS Neglegted Tropical Diseases 2012;6(3): e1564. [68] Farias LP, Cardoso FC, Miyasato PA, Montoya BO, Tararam CA, Roffato HK, Kawa‐ no T, Gazzinelli A, Correa-Oliveira R, Coulson PS, Wilson RA, Oliveira SC, Leite LC. Schistosoma mansoni Stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection. PLoS Neglected Tropical Diseases

[69] Araujo JM, Melo TT, Sena IC, Alves CC, Araujo N, Durães FD, Oliveira SC, Fonseca CT. Schistosoma mansoni schistosomula tegument (Smteg) immunization in absence of adjuvant induce IL-10 production by CD4+ cells and failed to protect mice against

[70] Butterworth AE, David JR, Franks D, Mahmoud AA, David PH, Sturrock RF, Houba V. Antibody-dependent eosinophil-mediated damage to 51Cr-labeled schistosomula of Schistosoma mansoni: damage by purified eosinophils. Journal of Experimental

challenge infection. Acta Tropica 2012; 124(2): 140-146. (PMID: 22842304).

against schistosome infection in mice. Vaccine 2001;20(3-4): 359-369.

seeding or gene gun delivery. Parasite Immunology 2002;24(4): 179-187.

soma mansoni infection. Parasite Immunology 2003;25(8-9): 429-437.

1998;177(5): 1364-1372.

196 Parasitic Diseases - Schistosomiasis

835-840.

es 2011;5(5): e1166.

2010;4(2): e597.

Medicine 1977;145(1): 136-150.


[83] Dean DA. Decreased binding of cytotoxic antibody by developing Schistosoma man‐ soni. Evidence for a surface change independent of host antigen adsorption and membrane turnover. Journal of Parasitolology 1977;63(3): 418-426.

[95] Tallima H, Salah M, El-Ridi R. In vitro and in vivo effects of unsaturated fatty acids on Schistosoma mansoni and S. haematobium lung-stage larvae. Journal of Parasitol‐

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

199

[96] El Ridi R, Tallima H. Equilibrium in lung schistosomula sphingomyelin breakdown and biosynthesis allows very small molecules, but not antibody, to access proteins at

[97] Tallima H, Hamada M, El Ridi R. Evaluation of cholesterol content and impact on an‐ tigen exposure in the outer lipid bilayer of adult schistosomes. Parasitology

[98] Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, Aslett MA, Bartholomeu DC, Blandin G, Caffrey CR, Coghlan A, Coulson R, Day TA, Delcher A, DeMarco R, Djikeng A, Eyre T, Gamble JA, Ghedin E, Gu Y, Hertz-Fowler C, Hirai H, Hirai Y, Houston R, Ivens A, Johnston DA, Lacerda D, Macedo CD, McVeigh P, Ning Z, Oliveira G, Overington JP, Parkhill J, Pertea M, Pierce RJ, Protasio AV, Quail MA, Rajandream MA, Rogers J, Sajid M, Salzberg SL, Stanke M, Tivey AR, White O, Williams DL, Wortman J, Wu W, Zamanian M, Zerlotini A, Fraser-Liggett CM, Barrell BG, El-Sayed NM. The genome

of the blood fluke Schistosoma mansoni. Nature 2009;460(7253): 352-358.

[99] Young ND, Jex AR, Li B, Liu S, Yang L, Xiong Z, Li Y, Cantacessi C, Hall RS, Xu X, Chen F, Wu X, Zerlotini A, Oliveira G, Hofmann A, Zhang G, Fang X, Kang Y, Campbell BE, Loukas A, Ranganathan S, Rollinson D, Rinaldi G, Brindley PJ, Yang H, Wang J, Wang J, Gasser RB. Whole-genome sequence of Schistosoma haematobi‐

[100] Tallima H, Al-Halbosiy MF, El Ridi R. Enzymatic activity and immunolocalization of Schistosoma mansoni and Schistosoma haematobium neutral sphingomyelinase. Mo‐

[101] El Ridi R, Aboueldahab M, Tallima H, Salah M, Mahana N, Fawzi S, Mohamed SH, Fahmy OM. In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium. Antimicrobial Agents and Chemotherapy

[102] El Ridi R, Tallima H, Salah M, Aboueldahab M, Fahmy OM, Al-Halbosiy MF, Mah‐ moud SS. Efficacy and mechanism of action of arachidonic acid in the treatment of hamsters infected with Schistosoma mansoni or Schistosoma haematobium. Interna‐

[103] El Ridi RAF, Tallima HA-M. Novel therapeutic and prevention approaches for schis‐ tosomiasis. Journal of Advanced Research 2012 (in press). http://dx.doi.org/10.1016/

the host-parasite interface. Journal of Parasitology 2006;92(4): 730-737.

ogy 2005;91(5): 1094-1102.

2007;134(Pt 12): 1775-1783.

um. Nature Genetics 2012;44(2): 221-225.

2010;54(8): 3383-3389.

j.jare.2012.05.002

lecular and Biochemical Parasitology 2011;178(1): 23-28.

tional Journal of Antimicrobial Agents 2012;39(3): 232-239.

[104] Skelly P. Fighting killer worms. Scientific American 2008;298(5): 94-99


[95] Tallima H, Salah M, El-Ridi R. In vitro and in vivo effects of unsaturated fatty acids on Schistosoma mansoni and S. haematobium lung-stage larvae. Journal of Parasitol‐ ogy 2005;91(5): 1094-1102.

[83] Dean DA. Decreased binding of cytotoxic antibody by developing Schistosoma man‐ soni. Evidence for a surface change independent of host antigen adsorption and

[84] Dessein A, Samuelson JC, Butterworth AE, Hogan M, Sherry BA, Vadas MA, David JR. Immune evasion by Schistosoma mansoni: loss of susceptibility to antibody or complement-dependent eosinophil attack by schistosomula cultured in medium free

[85] McLaren DJ, Terry RJ. The protective role of acquired host antigens during schisto‐

[86] Pearce EJ, Basch PF, Sher A. Evidence that the reduced surface antigenicity of devel‐ oping Schistosoma mansoni schistosomula is due to antigen shedding rather than

[87] Foley M, MacGregor AN, Kusel JR, Garland PB, Downie T, Moore I. The lateral diffu‐ sion of lipid probes in the surface membrane of Schistosoma mansoni. Journal of Cell

[88] Chiang C-P, Caulfield JP. Human lipoprotein binding to schistosomula of Schistoso‐ ma mansoni. Displacement by polyanions, parasite antigen masking, and persistence

[89] Kusel JR, Al-Adhami BH, Doenhoff MJ. The schistosome in the mammalian host: un‐ derstanding the mechanisms of adaptation. Parasitology 2007;134(Pt 11): 1477-1526

[90] Tallima H, El Ridi R. Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogen‐ ase is a lung-stage schistosomula surface membrane antigen. Folia Parasitology (Pra‐

[91] Skelly PJ, Wilson RA. Making sense of the schistosome surface. Advances in Parasi‐

[92] El Ridi R, Mohamed SH, Tallima H. Incubation of Schistosoma mansoni lung-stage schistosomula in corn oil exposes their surface membrane antigenic specificities.

[93] El Ridi R, Tallima H, Mohamed SH, Montash M. Depletion of Schistosoma mansoni lung-stage schistosomula cholesterol by methyl-beta-cyclodextrin dramatically in‐ creases specific antibody binding to surface membrane antigens. Journal of Parasitol‐

[94] Tallima H, El Ridi R. Methyl-beta-cyclodextrin treatment and filipin staining reveal the role of cholesterol in surface membrane antigen sequestration of Schistosoma mansoni and S. haematobium lung-stage larvae. Journal of Parasitology 2005;91(3):

in young larvae. American Journal of Pathology 1989:135(6): 1015-1024.

membrane turnover. Journal of Parasitolology 1977;63(3): 418-426.

of macromolecules. Parasitology 1981;82(3): 357-374.

Biology 1986;103(3): 807-818.

198 Parasitic Diseases - Schistosomiasis

ha) 2008;55(3): 180-186.

tology 2006;63: 185-284.

ogy 2004;90(4): 727-732.

720-725.

Journal of Parasitology 2003;89(5): 1064-1067.

some maturation. Parasite Immunology 1982; 4(2): 129-148.

host molecule acquisition. Parasite Immunology 1986;8 (1): 79-94.


[105] Knudsen GM, Medzihradszky KF, Lim KC, Hansell E, McKerrow JH. Proteomic analysis of Schistosoma mansoni cercarial secretions. Molecular and Cellular Proteo‐ mics 2005;4(12):1862-1875.

[118] Coulson PS. The radiation-attenuated vaccine against schistosomes in animal mod‐ els: paradigm for a human vaccine? Advances in Parasitology 1997;39: 271-336.

Solving the Riddle of the Lung-Stage Schistosomula Paved the Way to a Novel Remedy and an Efficacious Vaccine...

http://dx.doi.org/10.5772/52922

201

[119] Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood

[120] Ahmed SF, Oswald IP, Caspar P, Hieny S, Keefer L, Sher A, James SL. Developmen‐ tal differences determine larval susceptibility to nitric oxide-mediated killing in a murine model of vaccination against Schistosoma mansoni. Infection and Immunity

[121] Coulson PS, Smythies LE, Betts C, Mabbott NA, Sternberg JM, Wei XG, Liew FY, Wil‐ son RA. Nitric oxide produced in the lungs of mice immunized with the radiationattenuated schistosome vaccine is not the major agent causing challenge parasite

[122] Medina E. Neutrophil extracellular traps: a strategic tactic to defeat pathogens with potential consequences for the host. Journal of Innate Immunity 2009;1(3): 176-180.

[123] Menegazzi R, Decleva E, Dri P. Killing by neutrophil extracellular traps: fact or folk‐

[124] Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA, Butterworth AE. Compara‐ tive toxicity of purified human eosinophil granule cationic proteins for schistosomu‐ la of Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene

[125] Blanchard C, Rothenberg ME. Biology of the eosinophil. Advances in Immunology

[126] Schroeder JT. Basophils beyond effector cells of allergic inflammation. Advances in

[127] Anderson S, Shires VL, Wilson RA, Mountford AP. In the absence of IL-12, the induc‐ tion of Th1-mediated protective immunity by the attenuated schistosome vaccine is impaired, revealing an alternative pathway with Th2-type characteristics. European

[128] Jankovic D, Wynn TA, Kullberg MC, Hieny S, Caspar P, James S, Cheever AW, Sher A. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms. Journal of Immunology

[129] Mountford AP, Hogg KG, Coulson PS, Brombacher F. Signaling via interleukin-4 re‐ ceptor alpha chain is required for successful vaccination against schistosomiasis in

[130] Hewitson JP, Hamblin PA, Mountford AP. Immunity induced by the radiation-atte‐ nuated schistosome vaccine. Parasite Immunology 2005;27(7-8): 271-280.

2008; 112(4): 935-945.

1997;65(1): 219-226.

1985;34(4): 735-745.

2009;101: 81-121.

1999;162(1): 345-351.

elimination. Immunology 1998; 93(1);55-63.

lore? Blood 2012;119(5): 1214-1216.

Immunology 2009;101: 123-161.

Journal of Immunology 1998;28(9): 2827-2838.

BALB/c mice. Infection and Immunity 2001;69(1): 228-236.


[118] Coulson PS. The radiation-attenuated vaccine against schistosomes in animal mod‐ els: paradigm for a human vaccine? Advances in Parasitology 1997;39: 271-336.

[105] Knudsen GM, Medzihradszky KF, Lim KC, Hansell E, McKerrow JH. Proteomic analysis of Schistosoma mansoni cercarial secretions. Molecular and Cellular Proteo‐

[106] Curwen RS, Ashton PD, Sundaralingam S, Wilson RA. Identification of novel pro‐ teases and immunomodulators in the secretions of schistosome cercariae that facili‐

[107] Jang-Lee J, Curwen RS, Ashton PD, Tissot B, Mathieson W, Panico M, Dell A, Wilson RA, Haslam SM. Glycomics analysis of Schistosoma mansoni egg and cercarial secre‐

[108] Hansell E, Braschi S, Medzihradszky KF, Sajid M, Debnath M, Ingram J, Lim KC, McKerrow JH. Proteomic analysis of skin invasion by blood fluke larvae. PLoS Ne‐

[109] Liu F, Cui SJ, Hu W, Feng Z, Wang ZQ, Han ZG. Excretory/secretory proteome of the adult developmental stage of human blood fluke, Schistosoma japonicum. Molecular

[110] El Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secre‐ tory antigens as vaccine candidates against schistosomiasis. Vaccine 2009;27(5):

[111] Liao Q, Yuan X, Xiao H, Liu C, Lv Z, Zhao Y, Wu Z. Identifying Schistosoma japoni‐ cum excretory/secretory proteins and their interactions with host immune system.

[112] Mountford AP, Trottein F. Schistosomes in the skin: a balance between immune pri‐

[113] Jenkins SJ, Hewitson JP, Ferret-Bernard S, Mountford AP. Schistosome larvae stimu‐ late macrophage cytokine production through TLR4-dependent and -independent

[114] Jenkins SJ, Hewitson JP, Jenkins GR, Mountford AP. Modulation of the host's im‐ mune response by schistosome larvae. Parasite Immunology 2005;27(10-11): 385-393.

[115] Jenkins SJ, Mountford AP. Dendritic cells activated with products released by schis‐ tosome larvae drive Th2-type immune responses, which can be inhibited by manipu‐

[116] Paveley RA, Aynsley SA, Turner JD, Bourke CD, Jenkins SJ, Cook PC, Martinez-Po‐ mares L, Mountford AP. The Mannose Receptor (CD206) is an important pattern rec‐ ognition receptor (PRR) in the detection of the infective stage of the helminth Schistosoma mansoni and modulates IFNγ production. International Journal for Par‐

[117] Robinson MW, Hutchinson AT, Donnelly S, Dalton JP. Worm secretory molecules

lation of CD40 costimulation. Infection and Immunity 2005;73(1): 395-402.

ming and regulation. Trends in Parasitology 2004;20(5): 221-226.

pathways. International Immunology 2005;17(11): 1409-1418.

are causing alarm. Trends in Parasitology 2010;26(8): 371-372.

tate host entry. Molecular and Cellular Proteomics 2006;5(5): 835-844.

tions. Molecular and Cellular Proteomics 2007;6(9): 1485-1499.

glected Tropical Diseases 2008; 2(7): e262.

and Cellular Proteomics 2009;8(6): 1236-1251.

mics 2005;4(12):1862-1875.

200 Parasitic Diseases - Schistosomiasis

666-673.

PLoS One 2011;6(8): e23786.

asitology 2011;41(13-14): 1335-1345.


[131] Cêtre C, Cocude C, Pierrot C, Godin C, Capron A, Capron M, Khalife J. In vivo ex‐ pression of cytokine mRNA in rats infected with Schistosoma mansoni. Parasite Im‐

[132] Cêtre C, Pierrot C, Cocude C, Lafitte S, Capron A, Capron M, Khalife J. Profiles of Th1 and Th2 cytokines after primary and secondary infection by Schistosoma manso‐ ni in the semipermissive rat host. Infection and Immunity1999;67(6): 2713-2719.

[133] Fallon PG, Gibbons J, Vervenne RA, Richardson EJ, Fulford AJ, Kiarie S, Sturrock RF, Coulson PS, Deelder AM, Langermans JA, Thomas AW, Dunne DW. Juvenile rhesus monkeys have lower type 2 cytokine responses than adults after primary infection with Schistosoma mansoni. Journal of Infectious Diseases 2003;187(6): 939-945.

[134] Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, Colley DG, Secor WE. Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency vi‐ rus type 1 coinfection in humans. Infection and Immunity 2006;74(4): 2169-2176.

[135] Black CL, Mwinzi PN, Muok EM, Abudho B, Fitzsimmons CM, Dunne DW, Karanja DM, Secor WE, Colley DG. Influence of exposure history on the immunology and de‐ velopment of resistance to human Schistosomiasis mansoni. PLoS Neglected Tropical

[136] Figueiredo JP, Oliveira RR, Cardoso LS, Barnes KC, Grant AV, Carvalho EM, Araujo MI. Adult worm-specific IgE/IgG4 balance is associated with low infection levels of Schistosoma mansoni in an endemic area. Parasite Immunology 2012 (in press). doi:

[137] El Ridi R, Tallima H. Adjuvant selection for vaccination against murine schistosomia‐ sis. Scandinavian Journal of Immunology 2012; in press. DOI: 10.1111/j.

[138] El Ridi R, Tallima H. Vaccine-induced protection against murine schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines. Journal of Parasitology 2012; in press. DOI: http://dx.doi.org/10.1645/GE-3186.1

munology 1998;20(3): 135-142.

202 Parasitic Diseases - Schistosomiasis

Diseases 2010; 23;4(3): e637.

10.1111/pim.12001

1365-3083.2012.02768.x

*Edited by Rashika El Ridi*

Reports on schistosomiasis epidemiology and clinical features in Africa and Brazil, and development of novel drugs that affect the worm tegument, and vaccine based on excretory-secretory products and Type 2 cytokines.

Photo by defun / iStock

Parasitic Diseases - Schistosomiasis

Parasitic Diseases

Schistosomiasis